[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftntfCFJTUdBtYWXcUQW2WG9J7uBRKcTgFLDQklaCr8k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",[4],890,false,455,11,1148445,80,762,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Ovarian Cancer",25,{"name":18,"count":19},"Breast Cancer",20,{"name":21,"count":22},"Gynecologic Cancer",13,{"name":24,"count":25},"Parkinson Disease",12,{"name":27,"count":25},"Obesity",{"name":29,"count":9},"COVID-19",{"name":31,"count":9},"Endometrial Cancer",{"name":33,"count":34},"HIV Infections",9,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT07555639","An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity","2022-12-31","Genomic profile",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05750680","DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","2023-04-01","DOACs",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06020625","Mutational Oncology in Clinical Practice","2023-05-01","Diagnostic Test",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05728229","Effects of Nutrition on Post Stroke Fatigue","2024-09-29","Supplement with SiderAl® Med",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06283381","The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty","2025-01-31","Esomeprazole",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06715592","ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study","2025-03-31","Bleomicina",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05876598","BACTERIUM: Study for a Machine-learning-based Model to Predict Bloodstream Infections","2025-06-15","antibiotic treatments",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07158190","Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).","2025-06-30","Vaccine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT05122780","Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","2025-07","Antiplatelet Drug",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05868837","Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)","2025-07-31","Rituximab",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,139,157,175,193,211,229,247,268,298,326,344,372,392,444,483,507,540,569,596,614,632,650,676,699,724,749,818,856,897,926,953,982,1007,1036,1068,1086,1104,1122,1140,1167,1185,1209,1237,1262,1297,1319,1346,1373,1398,1423,1449,1473,1498,1522,1547,1572,1593,1619,1642,1666,1690,1708,1726,1744,1762,1780,1798,1816,1834,1852,1877,1895,1921,1947,1969,1997,2027,2049,2072,2101,2130,2156,2181,2206,2231,2253,2275,2297,2319,2347,2371,2389,2407,2432,2459,2477,2503,2525,2552,2570,2595,2613,2631,2658,2676,2700,2725,2743,2771,2789,2814,2832,2858,2876,2903,2921,2945,2969,2995,3020,3044,3078,3114,3154,3183,3201,3219,3246,3264,3282,3308,3326,3352,3376,3400,3425,3449,3473,3497,3515,3539,3566,3592,3618,3636,3662,3686,3714,3739,3764,3789,3807,3831,3856,3884,3908,3933,3957,3982,4009,4027,4045,4068,4091,4113,4138,4164,4190],{"intervention":95,"totalTrials":96,"cells":97},"Anticoagulant",2,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":123},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":122,"soonestReadout":79},[109],{"nctId":77,"briefTitle":78,"status":110,"phases":111,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":114,"interventions":116},"ACTIVE_NOT_RECRUITING",[91],"2021-07-01",120,[115],"Myocardial Infarction With Non-Obstructive Coronary Arteries",[80,117,118,119,120,121,95],"Statin","Beta blocker","ACEi\u002FARB","CCB","Nitrates",1,{"trials":124,"activeCount":122,"soonestReadout":130},[125],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":138},"NCT06284343","The Gynecological Cancer Associated Thrombosis (GynCAT) Study","RECRUITING",[],"2026-09-30","2024-04-15",1800,[134,135,21,15,136,31,137],"Cancer-associated Thrombosis","Venous Thromboembolism","Cervix Cancer","Vaginal Cancer",[95],{"intervention":80,"totalTrials":122,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":155},{"trials":142,"activeCount":100},[],{"trials":144,"activeCount":100},[],{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":122,"soonestReadout":79},[151],{"nctId":77,"briefTitle":78,"status":110,"phases":152,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":153,"interventions":154},[91],[115],[80,117,118,119,120,121,95],{"trials":156,"activeCount":100},[],{"intervention":117,"totalTrials":122,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":173},{"trials":160,"activeCount":100},[],{"trials":162,"activeCount":100},[],{"trials":164,"activeCount":100},[],{"trials":166,"activeCount":100},[],{"trials":168,"activeCount":122,"soonestReadout":79},[169],{"nctId":77,"briefTitle":78,"status":110,"phases":170,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":171,"interventions":172},[91],[115],[80,117,118,119,120,121,95],{"trials":174,"activeCount":100},[],{"intervention":118,"totalTrials":122,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":191},{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":100},[],{"trials":182,"activeCount":100},[],{"trials":184,"activeCount":100},[],{"trials":186,"activeCount":122,"soonestReadout":79},[187],{"nctId":77,"briefTitle":78,"status":110,"phases":188,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":189,"interventions":190},[91],[115],[80,117,118,119,120,121,95],{"trials":192,"activeCount":100},[],{"intervention":119,"totalTrials":122,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":209},{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":122,"soonestReadout":79},[205],{"nctId":77,"briefTitle":78,"status":110,"phases":206,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":207,"interventions":208},[91],[115],[80,117,118,119,120,121,95],{"trials":210,"activeCount":100},[],{"intervention":120,"totalTrials":122,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":100},[],{"trials":216,"activeCount":100},[],{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":122,"soonestReadout":79},[223],{"nctId":77,"briefTitle":78,"status":110,"phases":224,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":225,"interventions":226},[91],[115],[80,117,118,119,120,121,95],{"trials":228,"activeCount":100},[],{"intervention":121,"totalTrials":122,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":100},[],{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":122,"soonestReadout":79},[241],{"nctId":77,"briefTitle":78,"status":110,"phases":242,"primaryCompletion":79,"completion":79,"start":112,"enrollment":113,"conditions":243,"interventions":244},[91],[115],[80,117,118,119,120,121,95],{"trials":246,"activeCount":100},[],{"intervention":60,"totalTrials":122,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":266},{"trials":250,"activeCount":100},[],{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":100},[],{"trials":258,"activeCount":122,"soonestReadout":59},[259],{"nctId":57,"briefTitle":58,"status":128,"phases":260,"primaryCompletion":59,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":265},[91],"2026-06-30","2024-02-01",40,[27],[60],{"trials":267,"activeCount":100},[],{"intervention":269,"totalTrials":122,"cells":270},"Medical therapy",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":296},{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":100},[],{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":122,"soonestReadout":285},[281],{"nctId":282,"briefTitle":283,"status":128,"phases":284,"primaryCompletion":285,"completion":286,"start":69,"enrollment":287,"conditions":288,"interventions":295},"NCT06903312","Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.",[91],"2027-10-01","2028-04-01",409,[289,290,291,292,293,294],"Renal Cell Cancer","Kidney Neoplasm","Immunotherapy","Kidney Cancer","Surgery Programmed","Radiotherapy",[269],{"trials":297,"activeCount":100},[],{"intervention":299,"totalTrials":122,"cells":300},"Platinum + Gemcitabine",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":309,"NA":324},{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":122,"soonestReadout":315},[311],{"nctId":312,"briefTitle":313,"status":128,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":322},"NCT06820255","DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.",[91],"2026-01-07","2027-01-07","2025-01-07",135,[320,321],"Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable","Upper Tract Urothelial Cancer",[299,323],"Avelumab first-line maintenance",{"trials":325,"activeCount":100},[],{"intervention":323,"totalTrials":122,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":342},{"trials":329,"activeCount":100},[],{"trials":331,"activeCount":100},[],{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":122,"soonestReadout":315},[338],{"nctId":312,"briefTitle":313,"status":128,"phases":339,"primaryCompletion":315,"completion":316,"start":317,"enrollment":318,"conditions":340,"interventions":341},[91],[320,321],[299,323],{"trials":343,"activeCount":100},[],{"intervention":345,"totalTrials":122,"cells":346},"Standard systemic therapy (chemotherapy) without RT\u002FSBRT",{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":368,"NA":370},{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":100},[],{"trials":354,"activeCount":122,"soonestReadout":359},[355],{"nctId":356,"briefTitle":357,"status":110,"phases":358,"primaryCompletion":359,"completion":360,"start":361,"enrollment":362,"conditions":363,"interventions":367},"NCT06946420","SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy",[90],"2030-01-10","2031-01-10","2025-01-10",108,[364,365,366],"Radiation Therapy","SBRT","Pancreatic Cancer Metastatic",[345],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"intervention":85,"totalTrials":122,"cells":373},{"EARLY_PHASE1":374,"PHASE1":376,"PHASE2":378,"PHASE3":380,"PHASE4":388,"NA":390},{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":100},[],{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":122,"soonestReadout":84},[382],{"nctId":82,"briefTitle":83,"status":128,"phases":383,"primaryCompletion":84,"completion":84,"start":384,"enrollment":263,"conditions":385,"interventions":387},[90],"2022-02-28",[386],"Myasthenia Gravis, Generalized",[85],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"intervention":393,"totalTrials":96,"cells":394},"Nivolumab",{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":396,"activeCount":100},[],{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":122,"soonestReadout":405},[401],{"nctId":402,"briefTitle":403,"status":128,"phases":404,"primaryCompletion":405,"completion":406,"start":49,"enrollment":407,"conditions":408,"interventions":410},"NCT05203913","Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer",[89],"2025-12-15","2026-06-15",32,[409],"Muscle-Invasive Bladder Carcinoma",[393,411,412],"Nab paclitaxel","Cisplatin",{"trials":414,"activeCount":100},[],{"trials":416,"activeCount":100},[],{"trials":418,"activeCount":122,"soonestReadout":423},[419],{"nctId":420,"briefTitle":421,"status":128,"phases":422,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":425,"interventions":430},"NCT06532149","ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer",[],"2026-09-05","2024-08-05",[426,427,428,429],"NSCLC Stage IV","Sex Disorder","Hypogonadism, Male","Erectile Dysfunction",[431,432,433,434,435,436,437,438,439,440,393,441,442,443],"Alectinib","Brigatinib","Lorlatinib 100 mg","Osimertinib","Sotorasib","Dabrafenib","Trametinib","Selpercatinib","Pembrolizumab","Cemiplimab","Carboplatin","Pemetrexed","Paclitaxel",{"intervention":445,"totalTrials":96,"cells":446},"Donor FMT",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":122,"soonestReadout":457},[453,465],{"nctId":454,"briefTitle":455,"status":128,"phases":456,"primaryCompletion":457,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":464},"NCT04759001","FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae",[88,89],"2026-03-18","2026-08-15","2021-02-18",52,[462,463],"Enterobacteriaceae Infections","Multi-antibiotic Resistance",[445],{"nctId":466,"briefTitle":467,"status":468,"phases":469,"primaryCompletion":470,"completion":471,"start":459,"enrollment":472,"conditions":473,"interventions":475},"NCT04758507","Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma","COMPLETED",[88,89],"2024-12-16","2025-07-28",50,[474],"Renal Cell Carcinoma",[476],"donor FMT",{"trials":478,"activeCount":100},[],{"trials":480,"activeCount":100},[],{"trials":482,"activeCount":100},[],{"intervention":484,"totalTrials":122,"cells":485},"Donor - FMT",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":501,"PHASE4":503,"NA":505},{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":122,"soonestReadout":496},[492],{"nctId":493,"briefTitle":494,"status":128,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT05791396","FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae",[88,89],"2026-04","2024-02-08",36,[462,463],[484],{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"intervention":508,"totalTrials":122,"cells":509},"encorafenib + cetuximab + FOLFIRI",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":122,"soonestReadout":520},[516],{"nctId":517,"briefTitle":518,"status":128,"phases":519,"primaryCompletion":520,"completion":261,"start":521,"enrollment":16,"conditions":522,"interventions":533},"NCT06640166","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.",[89],"2025-12-31","2024-06-03",[523,524,525,526,527,528,529,530,531,532],"Colorectal Carcinoma","Colorectal Neoplasms","Colorectal Tumor","Colorectal Adenocarcinoma","Colorectal Cancer (CRC)","Colorectal Cancer","Colon Cancer","Colon Adenocarcinoma","Colon Carcinoma","Colon Neoplasm",[508],{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":100},[],{"intervention":541,"totalTrials":122,"cells":542},"CAR T cell",{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":122,"soonestReadout":553},[549],{"nctId":550,"briefTitle":551,"status":128,"phases":552,"primaryCompletion":553,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":562},"NCT06685042","Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases",[88,89],"2025-12","2024-11-29",8,[557,558,559,560,561],"Lupus Erythematosus, Systemic","System; Sclerosis","ANCA Associated Vasculitis","Dermatomyositis","Polymyositis",[541],{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":100},[],{"trials":568,"activeCount":100},[],{"intervention":570,"totalTrials":122,"cells":571},"single FMT",{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"trials":577,"activeCount":122,"soonestReadout":582},[578],{"nctId":579,"briefTitle":580,"status":128,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":585,"interventions":588},"NCT06071312","FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach",[88,89],"2026-09-24","2023-09-23",64,[586,587],"Clostridium Difficile","Ulcerative Colitis",[570,589],"sequential FMT",{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[],{"trials":595,"activeCount":100},[],{"intervention":589,"totalTrials":122,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":100},[],{"trials":603,"activeCount":122,"soonestReadout":582},[604],{"nctId":579,"briefTitle":580,"status":128,"phases":605,"primaryCompletion":582,"completion":582,"start":583,"enrollment":584,"conditions":606,"interventions":607},[88,89],[586,587],[570,589],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":100},[],{"intervention":411,"totalTrials":122,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":100},[],{"trials":621,"activeCount":122,"soonestReadout":405},[622],{"nctId":402,"briefTitle":403,"status":128,"phases":623,"primaryCompletion":405,"completion":406,"start":49,"enrollment":407,"conditions":624,"interventions":625},[89],[409],[393,411,412],{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":100},[],{"intervention":412,"totalTrials":122,"cells":633},{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":644,"PHASE4":646,"NA":648},{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":122,"soonestReadout":405},[640],{"nctId":402,"briefTitle":403,"status":128,"phases":641,"primaryCompletion":405,"completion":406,"start":49,"enrollment":407,"conditions":642,"interventions":643},[89],[409],[393,411,412],{"trials":645,"activeCount":100},[],{"trials":647,"activeCount":100},[],{"trials":649,"activeCount":100},[],{"intervention":651,"totalTrials":122,"cells":652},"Organoid-guided treatment",{"EARLY_PHASE1":653,"PHASE1":655,"PHASE2":657,"PHASE3":670,"PHASE4":672,"NA":674},{"trials":654,"activeCount":100},[],{"trials":656,"activeCount":100},[],{"trials":658,"activeCount":122,"soonestReadout":664},[659],{"nctId":660,"briefTitle":661,"status":662,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":16,"conditions":667,"interventions":669},"NCT07214649","Organoids for Bile Leaks","NOT_YET_RECRUITING",[89],"2030-06","2030-12","2026-01",[668],"Biliary Anastomosis Complication",[651],{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[],{"trials":675,"activeCount":100},[],{"intervention":65,"totalTrials":122,"cells":677},{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":679,"activeCount":100},[],{"trials":681,"activeCount":100},[],{"trials":683,"activeCount":122,"soonestReadout":64},[684],{"nctId":62,"briefTitle":63,"status":110,"phases":685,"primaryCompletion":64,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":692},[89],"2027-02-01","2023-05-23",18,[690,691],"Paget Disease of the Vulva","Vulva Cancer",[65],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"trials":698,"activeCount":100},[],{"intervention":700,"totalTrials":122,"cells":701},"FMT",{"EARLY_PHASE1":702,"PHASE1":704,"PHASE2":706,"PHASE3":718,"PHASE4":720,"NA":722},{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":122,"soonestReadout":712},[708],{"nctId":709,"briefTitle":710,"status":128,"phases":711,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT05739864","Superdonor FMT in Patients With Ulcerative Colitis",[88,89],"2027-02-14","2023-02-13",42,[716],"Active Ulcerative Colitis",[700],{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[],{"trials":723,"activeCount":100},[],{"intervention":725,"totalTrials":122,"cells":726},"CDK4\u002F6 Inhibitor",{"EARLY_PHASE1":727,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":747},{"trials":728,"activeCount":122,"soonestReadout":733},[729],{"nctId":730,"briefTitle":731,"status":128,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":738},"NCT06959979","Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma",[87],"2026-08-31","2024-11-25",60,[737],"Medulloblastoma, Childhood",[725],{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"intervention":441,"totalTrials":750,"cells":751},5,{"EARLY_PHASE1":752,"PHASE1":754,"PHASE2":756,"PHASE3":793,"PHASE4":810,"NA":812},{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[758,771,783],{"nctId":759,"briefTitle":760,"status":761,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT04261465","NUVOLA TRIAL Open-label Multicentre Study","UNKNOWN",[89],"2020-12-01","2022-12-01","2019-12-01",35,[768],"High Grade Serous Ovarian Cancer",[770,443,441],"Olaparib",{"nctId":772,"briefTitle":773,"status":761,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT03462212","Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination",[88,89],"2025-03-01","2021-03-17",290,[779],"Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer",[441,443,781,782],"Bevacizumab","Rucaparib",{"nctId":784,"briefTitle":785,"status":761,"phases":786,"primaryCompletion":787,"completion":787,"start":459,"enrollment":788,"conditions":789,"interventions":791},"NCT04238988","Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer",[89],"2023-09-01",45,[790],"Locally Advanced Cervical Cancer",[439,441,792],"Taxol",{"trials":794,"activeCount":100},[795],{"nctId":796,"briefTitle":797,"status":468,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":804},"NCT02903004","Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients",[90],"2018-12-20","2016-04-11",242,[803],"Ovarian Neoplasms",[805,806,807,808,809,441],"Trabectedin","Pegylated Liposomal Doxorubicin","Topotecan","Gemcitabine","Weekly Paclitaxel",{"trials":811,"activeCount":100},[],{"trials":813,"activeCount":122,"soonestReadout":423},[814],{"nctId":420,"briefTitle":421,"status":128,"phases":815,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":816,"interventions":817},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":443,"totalTrials":819,"cells":820},4,{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":835,"PHASE4":848,"NA":850},{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"trials":826,"activeCount":100},[827,831],{"nctId":759,"briefTitle":760,"status":761,"phases":828,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":829,"interventions":830},[89],[768],[770,443,441],{"nctId":772,"briefTitle":773,"status":761,"phases":832,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":833,"interventions":834},[88,89],[779],[441,443,781,782],{"trials":836,"activeCount":100},[837],{"nctId":838,"briefTitle":839,"status":761,"phases":840,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":843,"interventions":844},"NCT04679064","Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment",[90],"2025-01-01",427,[15],[845,846,847,443,808,807,781],"Niraparib","Dostarlimab","Pegylated liposomal doxorubicin",{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":122,"soonestReadout":423},[852],{"nctId":420,"briefTitle":421,"status":128,"phases":853,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":854,"interventions":855},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":439,"totalTrials":819,"cells":857},{"EARLY_PHASE1":858,"PHASE1":860,"PHASE2":862,"PHASE3":887,"PHASE4":889,"NA":891},{"trials":859,"activeCount":100},[],{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[864,873,877],{"nctId":865,"briefTitle":866,"status":761,"phases":867,"primaryCompletion":868,"completion":868,"start":869,"enrollment":788,"conditions":870,"interventions":872},"NCT04211103","Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions",[89],"2024-09-01","2020-10-14",[871],"Cervical, Vaginal and Vulval Inflammatory Diseases",[439],{"nctId":784,"briefTitle":785,"status":761,"phases":874,"primaryCompletion":787,"completion":787,"start":459,"enrollment":788,"conditions":875,"interventions":876},[89],[790],[439,441,792],{"nctId":878,"briefTitle":879,"status":761,"phases":880,"primaryCompletion":69,"completion":69,"start":881,"enrollment":882,"conditions":883,"interventions":886},"NCT04375956","Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients",[89],"2021-04-26",100,[15,884,885],"Primary Peritoneal Carcinoma","Fallopian Tube Cancer",[439],{"trials":888,"activeCount":100},[],{"trials":890,"activeCount":100},[],{"trials":892,"activeCount":122,"soonestReadout":423},[893],{"nctId":420,"briefTitle":421,"status":128,"phases":894,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":895,"interventions":896},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":434,"totalTrials":96,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":920},{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[],{"trials":904,"activeCount":100},[],{"trials":906,"activeCount":100},[],{"trials":908,"activeCount":100},[909],{"nctId":910,"briefTitle":911,"status":761,"phases":912,"primaryCompletion":913,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT05785208","Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.",[91],"2024-02-28","2025-10-31","2022-06-28",122,[918],"Non Small Cell Lung Cancer",[434],{"trials":921,"activeCount":122,"soonestReadout":423},[922],{"nctId":420,"briefTitle":421,"status":128,"phases":923,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":924,"interventions":925},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":927,"totalTrials":122,"cells":928},"Placenta organoids treatment",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":930,"activeCount":100},[],{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":100},[],{"trials":940,"activeCount":122,"soonestReadout":945},[941],{"nctId":942,"briefTitle":943,"status":662,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":19,"conditions":947,"interventions":952},"NCT06893978","Placental Organoids Development: Application in the Study of the Human Reproduction Pathophysiology.",[],"2027-11","2025-05-20",[948,949,950,951],"Preeclampsia","Pregnancy Loss","Preterm Birth","Healthy",[927],{"intervention":954,"totalTrials":122,"cells":955},"Genetic profiling of all eligible patients",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":100},[],{"trials":963,"activeCount":100},[],{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":122,"soonestReadout":972},[968],{"nctId":969,"briefTitle":970,"status":128,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":981},"NCT06892964","Institution of an Italian Registry and Biobank for Biological Sample Collection",[92],"2043-06-27","2044-06-27","2024-06-27",70,[977,978,979,980],"Lymphatic Malformation","Lymphatic Abnormality","Lymphangioma","Lymphatic Abnormalities",[954],{"intervention":983,"totalTrials":122,"cells":984},"DNA sequencing",{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":986,"activeCount":100},[],{"trials":988,"activeCount":100},[],{"trials":990,"activeCount":100},[],{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":122,"soonestReadout":1001},[997],{"nctId":998,"briefTitle":999,"status":662,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":868,"enrollment":1002,"conditions":1003,"interventions":1006},"NCT06521125","Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis",[],"2026-09-01",600,[1004,1005],"Familial Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis",[983],{"intervention":1008,"totalTrials":122,"cells":1009},"Relugolix\u002Festradiol\u002Fnorethisterone acetate",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":100},[],{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":100},[],{"trials":1019,"activeCount":100},[],{"trials":1021,"activeCount":122,"soonestReadout":1026},[1022],{"nctId":1023,"briefTitle":1024,"status":128,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1035},"NCT06953076","Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study",[],"2026-05-02","2027-05-02","2025-05-02",111,[1031,1032,1033,1034],"Uterine Bleeding","Uterine Leiomyomas","Uterine Hemorrhage","Uterine Neoplasms",[1008],{"intervention":1037,"totalTrials":122,"cells":1038},"Enzalutamide",{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1045,"PHASE4":1047,"NA":1049},{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":100},[],{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":122,"soonestReadout":1055},[1051],{"nctId":1052,"briefTitle":1053,"status":128,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":1058,"conditions":1059,"interventions":1063},"NCT06652607","PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer",[],"2026-11-01","2028-04-30","2024-12-20",152,[1060,1061,1062],"Prostate Cancer","Metastatic Cancer","Castrate Sensitive Prostate Cancer",[1037,1064,1065,1066,1067],"Apalutamide (Erleada™) 60 mg or 240 mg","Darolutamide (Nubeqa®) 300 mg","Taxotere","Abiraterone acetate + Prednisone or Prednisolone",{"intervention":1064,"totalTrials":122,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":122,"soonestReadout":1055},[1082],{"nctId":1052,"briefTitle":1053,"status":128,"phases":1083,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":1058,"conditions":1084,"interventions":1085},[],[1060,1061,1062],[1037,1064,1065,1066,1067],{"intervention":1065,"totalTrials":122,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1089,"activeCount":100},[],{"trials":1091,"activeCount":100},[],{"trials":1093,"activeCount":100},[],{"trials":1095,"activeCount":100},[],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":122,"soonestReadout":1055},[1100],{"nctId":1052,"briefTitle":1053,"status":128,"phases":1101,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":1058,"conditions":1102,"interventions":1103},[],[1060,1061,1062],[1037,1064,1065,1066,1067],{"intervention":1066,"totalTrials":122,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1116},{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[],{"trials":1117,"activeCount":122,"soonestReadout":1055},[1118],{"nctId":1052,"briefTitle":1053,"status":128,"phases":1119,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":1058,"conditions":1120,"interventions":1121},[],[1060,1061,1062],[1037,1064,1065,1066,1067],{"intervention":1067,"totalTrials":122,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1132,"NA":1134},{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[],{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":122,"soonestReadout":1055},[1136],{"nctId":1052,"briefTitle":1053,"status":128,"phases":1137,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":1058,"conditions":1138,"interventions":1139},[],[1060,1061,1062],[1037,1064,1065,1066,1067],{"intervention":1141,"totalTrials":122,"cells":1142},"Development and characterization of PDOs",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1153},{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":122,"soonestReadout":1159},[1155],{"nctId":1156,"briefTitle":1157,"status":662,"phases":1158,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":882,"conditions":1161,"interventions":1165},"NCT06781372","Patient's Derived Organoids for Drug Screening in Glioblastoma",[92],"2028-01-31","2025-04-01",[1162,1163,1164],"Glioblastoma","Glioblastoma Multiforme (GBM)","Glioblastoma Multiforme, Adult",[1141,1166],"Evaluation of the effects of epigenetic and splicing inhibitors on viability and gene expression signatures of GBM PDOs and GSCs",{"intervention":1166,"totalTrials":122,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"trials":1180,"activeCount":122,"soonestReadout":1159},[1181],{"nctId":1156,"briefTitle":1157,"status":662,"phases":1182,"primaryCompletion":1159,"completion":1159,"start":1160,"enrollment":882,"conditions":1183,"interventions":1184},[92],[1162,1163,1164],[1141,1166],{"intervention":1186,"totalTrials":122,"cells":1187},"Whole genome sequencing",{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1189,"activeCount":100},[],{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":122,"soonestReadout":1204},[1200],{"nctId":1201,"briefTitle":1202,"status":128,"phases":1203,"primaryCompletion":1204,"completion":1204,"start":1205,"enrollment":113,"conditions":1206,"interventions":1208},"NCT07512804","Post-Transplant Diabetes Outcomes Prediction",[92],"2027-02-28","2024-08-31",[1207],"New Onset Diabetes After Transplantation",[1186],{"intervention":1210,"totalTrials":122,"cells":1211},"SonoVue",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1220,"NA":1222},{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[],{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":122,"soonestReadout":1228},[1224],{"nctId":1225,"briefTitle":1226,"status":662,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1236},"NCT07365709","Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension",[92],"2026-07-31","2026-12-31","2026-02-01",107,[1233,1234,1235],"Portal Hypertension","Spleen Disease","Cirrhosis",[1210],{"intervention":1238,"totalTrials":122,"cells":1239},"Evaluation of HS1,2 polymorphisms",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[],{"trials":1251,"activeCount":122,"soonestReadout":1256},[1252],{"nctId":1253,"briefTitle":1254,"status":128,"phases":1255,"primaryCompletion":1256,"completion":130,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1261},"NCT06758128","Genetic and Immunity in Heart Failure",[],"2026-07-15","2025-02-04",215,[1260],"Heart Failure",[1238],{"intervention":1263,"totalTrials":122,"cells":1264},"Hospital-Based Vaccination Pathway",{"EARLY_PHASE1":1265,"PHASE1":1267,"PHASE2":1269,"PHASE3":1271,"PHASE4":1273,"NA":1275},{"trials":1266,"activeCount":100},[],{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"trials":1274,"activeCount":100},[],{"trials":1276,"activeCount":122,"soonestReadout":1281},[1277],{"nctId":1278,"briefTitle":1279,"status":662,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1296},"NCT07391046","Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients",[],"2027-02","2026-02",1500,[1285,1286,1287,1288,1289,1290,1291,1292,1293,1294,1295],"Chronic Disease","Immunocompromised","HIV Infection","Chronic Kidney Disease","Solid Organ Transplantation","Hematopoietic Stem Cell Transplantation","Cancer","Autoimmune Diseases","Inflammatory Bowel Disease","Asplenia","Frailty",[1263],{"intervention":75,"totalTrials":122,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":100},[],{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":122,"soonestReadout":74},[1311],{"nctId":72,"briefTitle":73,"status":110,"phases":1312,"primaryCompletion":74,"completion":1313,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},[],"2025-09-30","2024-06-30",30,[1317],"Dengue",[75],{"intervention":1320,"totalTrials":122,"cells":1321},"DNA, RNA, ctDNA, metabolomics",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1330,"NA":1332},{"trials":1323,"activeCount":100},[],{"trials":1325,"activeCount":100},[],{"trials":1327,"activeCount":100},[],{"trials":1329,"activeCount":100},[],{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":122,"soonestReadout":1338},[1334],{"nctId":1335,"briefTitle":1336,"status":662,"phases":1337,"primaryCompletion":1338,"completion":1229,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1345},"NCT06582108","UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT",[],"2026-09-15","2024-09-15",190,[1342,1343,1344],"Uterine Sarcoma","Vulvar Cancer","Non Epithelial Ovarian Cancers (NEOC)",[1320],{"intervention":1347,"totalTrials":122,"cells":1348},"Sideral Folico",{"EARLY_PHASE1":1349,"PHASE1":1351,"PHASE2":1353,"PHASE3":1355,"PHASE4":1357,"NA":1359},{"trials":1350,"activeCount":100},[],{"trials":1352,"activeCount":100},[],{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":122,"soonestReadout":1365},[1361],{"nctId":1362,"briefTitle":1363,"status":662,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1372},"NCT07163390","Iron Deficiency Anemia in the Second and Third Trimester of Pregnancy",[92],"2027-07-15","2027-09-15","2025-09-15",82,[1370,1371],"Anemia, Iron Deficiency","Pregnancy Anemia",[1347],{"intervention":1374,"totalTrials":122,"cells":1375},"comprhensive spatial transcriptomic profile on lesional skin biopsies",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1377,"activeCount":100},[],{"trials":1379,"activeCount":100},[],{"trials":1381,"activeCount":100},[],{"trials":1383,"activeCount":100},[],{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":122,"soonestReadout":1392},[1388],{"nctId":1389,"briefTitle":1390,"status":128,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":263,"conditions":1395,"interventions":1397},"NCT06884163","Immune Signature of Chronic Hand Eczema Unveiled by Spatial Transcriptomics and Single-Cell Proteomics",[92],"2026-01-01","2027-01-01","2025-01-13",[1396],"Hand Eczema",[1374],{"intervention":1399,"totalTrials":122,"cells":1400},"Cabotegravir\u002FRilpivirine",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[],{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":122,"soonestReadout":1417},[1413],{"nctId":1414,"briefTitle":1415,"status":662,"phases":1416,"primaryCompletion":1417,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT07579546","PERsistance of Long-Acting inJEctable CAB+RPV in a Cohort of Virologically-suppressed PLWH: a Real-life Study",[],"2027-06-01","2026-06-01",200,[1421],"HIV-1-infection",[1399],{"intervention":1424,"totalTrials":122,"cells":1425},"Whole Exome Sequencing",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1432,"PHASE4":1434,"NA":1436},{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[],{"trials":1433,"activeCount":100},[],{"trials":1435,"activeCount":100},[],{"trials":1437,"activeCount":122,"soonestReadout":1442},[1438],{"nctId":1439,"briefTitle":1440,"status":128,"phases":1441,"primaryCompletion":1442,"completion":1443,"start":1444,"enrollment":1283,"conditions":1445,"interventions":1448},"NCT06926127","Genomic Profiling of Genetic and Rare Diseases",[92],"2026-04-30","2030-02-28","2024-11-05",[1446,1447],"Rare Diseases","Genetic Disease",[1424],{"intervention":1450,"totalTrials":122,"cells":1451},"Cyclin-dependent Kinase 4\u002F6 Inhibitor",{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"trials":1457,"activeCount":100},[],{"trials":1459,"activeCount":100},[],{"trials":1461,"activeCount":100},[],{"trials":1463,"activeCount":122,"soonestReadout":1468},[1464],{"nctId":1465,"briefTitle":1466,"status":110,"phases":1467,"primaryCompletion":1468,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1472},"NCT07008508","Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4\u002F6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4\u002F6 Inhibitors Therapy (BRAVE-Cyclin) Study",[],"2032-05","2025-05-15",300,[18],[1450],{"intervention":1474,"totalTrials":122,"cells":1475},"Standard systemic therapy",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1482,"PHASE4":1484,"NA":1486},{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[],{"trials":1483,"activeCount":100},[],{"trials":1485,"activeCount":100},[],{"trials":1487,"activeCount":122,"soonestReadout":1492},[1488],{"nctId":1489,"briefTitle":1490,"status":110,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":362,"conditions":1495,"interventions":1497},"NCT06922279","First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial",[92],"2029-10-30","2029-11-30","2024-11-30",[1496],"Gastroesophageal Cancer (GC)",[1474],{"intervention":50,"totalTrials":122,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[],{"trials":1507,"activeCount":100},[],{"trials":1509,"activeCount":100},[],{"trials":1511,"activeCount":122,"soonestReadout":49},[1512],{"nctId":47,"briefTitle":48,"status":128,"phases":1513,"primaryCompletion":49,"completion":1514,"start":1515,"enrollment":1516,"conditions":1517,"interventions":1521},[92],"2032-01","2022-01-01",20000,[1518,1519,1520],"Genome Instability","Genetic Predisposition to Disease","Gene Rearrangement",[50],{"intervention":1523,"totalTrials":122,"cells":1524},"Fluoropyrimidine",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1533,"NA":1535},{"trials":1526,"activeCount":100},[],{"trials":1528,"activeCount":100},[],{"trials":1530,"activeCount":100},[],{"trials":1532,"activeCount":100},[],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":122,"soonestReadout":1541},[1537],{"nctId":1538,"briefTitle":1539,"status":110,"phases":1540,"primaryCompletion":1541,"completion":1542,"start":1543,"enrollment":1470,"conditions":1544,"interventions":1546},"NCT07494578","Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC",[],"2027-07-01","2027-08-01","2025-07-01",[1545],"Colon Cancer Metastatic",[1523],{"intervention":1548,"totalTrials":122,"cells":1549},"Intravenous iron",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":100},[],{"trials":1557,"activeCount":100},[],{"trials":1559,"activeCount":100},[],{"trials":1561,"activeCount":122,"soonestReadout":1566},[1562],{"nctId":1563,"briefTitle":1564,"status":662,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":882,"conditions":1569,"interventions":1571},"NCT06583902","Management of Anemia in Patients with EndocaRditis Infectious Candidates for Cardiac Surgery: the AMERICA Study",[],"2025-10","2025-10-30","2024-10",[1570],"Infective Endocarditis",[1548],{"intervention":55,"totalTrials":122,"cells":1573},{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[],{"trials":1579,"activeCount":100},[],{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":122,"soonestReadout":54},[1586],{"nctId":52,"briefTitle":53,"status":128,"phases":1587,"primaryCompletion":54,"completion":553,"start":1588,"enrollment":113,"conditions":1589,"interventions":1592},[92],"2022-11-07",[1590,1591],"Fatigue","Stroke",[55],{"intervention":1594,"totalTrials":122,"cells":1595},"PRS",{"EARLY_PHASE1":1596,"PHASE1":1598,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":122,"soonestReadout":1612},[1608],{"nctId":1609,"briefTitle":1610,"status":128,"phases":1611,"primaryCompletion":1612,"completion":1613,"start":1614,"enrollment":1615,"conditions":1616,"interventions":1618},"NCT05883878","Innovative Approaches for Personalised Cardiovascular Prevention",[92],"2025-11","2026-05","2023-07-24",1020,[1617],"Cardiovascular Diseases",[1594],{"intervention":1620,"totalTrials":122,"cells":1621},"antithrombotic drugs",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":122,"soonestReadout":945},[1634],{"nctId":1635,"briefTitle":1636,"status":662,"phases":1637,"primaryCompletion":945,"completion":945,"start":666,"enrollment":1638,"conditions":1639,"interventions":1641},"NCT07338071","Antithrombotic Therapy at the End of Life: The PEACE Study",[],410,[1640],"Palliative Care",[1620],{"intervention":1643,"totalTrials":122,"cells":1644},"low-fat diet, supplements, statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, or other lipid-lowering agents",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1651,"PHASE4":1653,"NA":1655},{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":100},[],{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":122,"soonestReadout":1229},[1657],{"nctId":1658,"briefTitle":1659,"status":662,"phases":1660,"primaryCompletion":1229,"completion":1229,"start":1392,"enrollment":1661,"conditions":1662,"interventions":1665},"NCT07256171","COAST Study - Cholesterol Optimization After Stroke",[],500,[1663,1664],"Stroke (CVA) or Transient Ischemic Attack","Cerebral Hemorrhage",[1643],{"intervention":1667,"totalTrials":122,"cells":1668},"Atezolizumab",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[],{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":122,"soonestReadout":1685},[1681],{"nctId":1682,"briefTitle":1683,"status":128,"phases":1684,"primaryCompletion":1685,"completion":1685,"start":1686,"enrollment":882,"conditions":1687,"interventions":1689},"NCT05797493","Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer",[],"2027-06","2022-10-04",[1688],"Small Cell Lung Cancer",[1667],{"intervention":431,"totalTrials":122,"cells":1691},{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1698,"PHASE4":1700,"NA":1702},{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":122,"soonestReadout":423},[1704],{"nctId":420,"briefTitle":421,"status":128,"phases":1705,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1706,"interventions":1707},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":432,"totalTrials":122,"cells":1709},{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[],{"trials":1715,"activeCount":100},[],{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":122,"soonestReadout":423},[1722],{"nctId":420,"briefTitle":421,"status":128,"phases":1723,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1724,"interventions":1725},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":433,"totalTrials":122,"cells":1727},{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1732,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[],{"trials":1733,"activeCount":100},[],{"trials":1735,"activeCount":100},[],{"trials":1737,"activeCount":100},[],{"trials":1739,"activeCount":122,"soonestReadout":423},[1740],{"nctId":420,"briefTitle":421,"status":128,"phases":1741,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1742,"interventions":1743},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":435,"totalTrials":122,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1748,"PHASE2":1750,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[],{"trials":1751,"activeCount":100},[],{"trials":1753,"activeCount":100},[],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":122,"soonestReadout":423},[1758],{"nctId":420,"briefTitle":421,"status":128,"phases":1759,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1760,"interventions":1761},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":436,"totalTrials":122,"cells":1763},{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1768,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[],{"trials":1769,"activeCount":100},[],{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":122,"soonestReadout":423},[1776],{"nctId":420,"briefTitle":421,"status":128,"phases":1777,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1778,"interventions":1779},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":437,"totalTrials":122,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":100},[],{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":122,"soonestReadout":423},[1794],{"nctId":420,"briefTitle":421,"status":128,"phases":1795,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1796,"interventions":1797},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":438,"totalTrials":122,"cells":1799},{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":122,"soonestReadout":423},[1812],{"nctId":420,"briefTitle":421,"status":128,"phases":1813,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1814,"interventions":1815},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":440,"totalTrials":122,"cells":1817},{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1824,"PHASE4":1826,"NA":1828},{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[],{"trials":1825,"activeCount":100},[],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":122,"soonestReadout":423},[1830],{"nctId":420,"briefTitle":421,"status":128,"phases":1831,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1832,"interventions":1833},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":442,"totalTrials":122,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1842,"PHASE4":1844,"NA":1846},{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[],{"trials":1841,"activeCount":100},[],{"trials":1843,"activeCount":100},[],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":122,"soonestReadout":423},[1848],{"nctId":420,"briefTitle":421,"status":128,"phases":1849,"primaryCompletion":423,"completion":130,"start":424,"enrollment":11,"conditions":1850,"interventions":1851},[],[426,427,428,429],[431,432,433,434,435,436,437,438,439,440,393,441,442,443],{"intervention":1853,"totalTrials":122,"cells":1854},"AIRE single gene sequencing",{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1856,"activeCount":100},[],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"trials":1862,"activeCount":100},[],{"trials":1864,"activeCount":100},[],{"trials":1866,"activeCount":122,"soonestReadout":1871},[1867],{"nctId":1868,"briefTitle":1869,"status":128,"phases":1870,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":263,"conditions":1873,"interventions":1875},"NCT06941584","Analysis of the Role of AIRE in Autoimmune Neurological Diseases Associated With Autoantibodies",[],"2027-01-06","2024-11-06",[1874],"AIRE Deficiency",[1853,1876],"Molecular typing of HLA class I and II alleles",{"intervention":1876,"totalTrials":122,"cells":1878},{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1880,"activeCount":100},[],{"trials":1882,"activeCount":100},[],{"trials":1884,"activeCount":100},[],{"trials":1886,"activeCount":100},[],{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":122,"soonestReadout":1871},[1891],{"nctId":1868,"briefTitle":1869,"status":128,"phases":1892,"primaryCompletion":1871,"completion":1871,"start":1872,"enrollment":263,"conditions":1893,"interventions":1894},[],[1874],[1853,1876],{"intervention":1896,"totalTrials":122,"cells":1897},"Blood Exams, Fluid Biomarkers, Genetics",{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1904,"PHASE4":1906,"NA":1908},{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[],{"trials":1903,"activeCount":100},[],{"trials":1905,"activeCount":100},[],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":122,"soonestReadout":1914},[1910],{"nctId":1911,"briefTitle":1912,"status":662,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1419,"conditions":1916,"interventions":1920},"NCT06896201","Comfortage - AD Prevention Strategies",[92],"2027-03","2025-09",[1917,1918,1919],"Alzheimer Disease","Subjective Cognitive Impairment","Mild Cognitive Impairment",[1896],{"intervention":1922,"totalTrials":122,"cells":1923},"target therapies",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1925,"activeCount":100},[],{"trials":1927,"activeCount":100},[],{"trials":1929,"activeCount":100},[],{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":122,"soonestReadout":1940},[1936],{"nctId":1937,"briefTitle":1938,"status":128,"phases":1939,"primaryCompletion":1940,"completion":1941,"start":1942,"enrollment":1943,"conditions":1944,"interventions":1946},"NCT06882148","Drug Survival of Target Therapies in Atopic Dermatitis",[],"2026-10-30","2028-10-30","2023-10-12",1167,[1945],"Atopic Dermatitis",[1922],{"intervention":40,"totalTrials":122,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":122,"soonestReadout":39},[1961],{"nctId":37,"briefTitle":38,"status":110,"phases":1962,"primaryCompletion":39,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1968},[92],"2032-12-31","2019-11-21",4000,[529,18,15,1967],"Genetic Risk Factors",[40],{"intervention":1970,"totalTrials":122,"cells":1971},"Illumina Infinium Global Screening Array 4.0",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"trials":1983,"activeCount":122,"soonestReadout":1988},[1984],{"nctId":1985,"briefTitle":1986,"status":662,"phases":1987,"primaryCompletion":1988,"completion":1989,"start":914,"enrollment":1990,"conditions":1991,"interventions":1996},"NCT07188506","Youth Suicide Risk Factors, Reduction of Suicide Risk Factor in Youth People",[92],"2027-12-31","2028-10-31",180,[1992,1993,1994,1995],"Mood Disorders","Suicide, Attempted","Suicidal Ideation","Suicide Prevention",[1970],{"intervention":1998,"totalTrials":122,"cells":1999},"Design of patient specific ASO",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":2001,"activeCount":100},[],{"trials":2003,"activeCount":100},[],{"trials":2005,"activeCount":100},[],{"trials":2007,"activeCount":100},[],{"trials":2009,"activeCount":100},[],{"trials":2011,"activeCount":122,"soonestReadout":2016},[2012],{"nctId":2013,"briefTitle":2014,"status":662,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":25,"conditions":2019,"interventions":2026},"NCT07535372","ASO Treatment for Syndromic Craniosynostoses",[],"2027-04-20","2028-04-20","2026-04-20",[2020,2021,2022,2023,2024,2025],"Craniosynostoses","Crouzon Syndrome","Saethre Chotzen Syndrome","Muenke Syndrome","Pfeiffer Syndrome","Apert Syndrome",[1998],{"intervention":70,"totalTrials":122,"cells":2028},{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2035,"PHASE4":2037,"NA":2039},{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":100},[],{"trials":2036,"activeCount":100},[],{"trials":2038,"activeCount":100},[],{"trials":2040,"activeCount":122,"soonestReadout":69},[2041],{"nctId":67,"briefTitle":68,"status":128,"phases":2042,"primaryCompletion":69,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2048},[],"2025-12-30","2021-11-03",5000,[2047],"Infection, Bloodstream",[70],{"intervention":45,"totalTrials":122,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[],{"trials":2062,"activeCount":122,"soonestReadout":44},[2063],{"nctId":42,"briefTitle":43,"status":110,"phases":2064,"primaryCompletion":44,"completion":2065,"start":2066,"enrollment":2067,"conditions":2068,"interventions":2071},[],"2025-05-01","2021-05-13",23,[2069,2070],"Atrial Fibrillation","Thromboembolism, Venous",[45],{"intervention":2073,"totalTrials":122,"cells":2074},"Iron",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[],{"trials":2080,"activeCount":100},[],{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":122,"soonestReadout":1204},[2087],{"nctId":2088,"briefTitle":2089,"status":128,"phases":2090,"primaryCompletion":1204,"completion":1204,"start":2091,"enrollment":2092,"conditions":2093,"interventions":2100},"NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery",[],"2025-02-24",464,[2094,2095,2096,2097,2098,2099],"Anemia","Anemia, Iron-Deficiency","Iron Deficiency Anemia Treatment","Iron Deficiency Anemia (IDA)","Cardiac Surgical Patients","Blood Loss, Surgical",[2073],{"intervention":2102,"totalTrials":122,"cells":2103},"Lactobacillus Crispatus M247",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2110,"PHASE4":2112,"NA":2128},{"trials":2105,"activeCount":100},[],{"trials":2107,"activeCount":100},[],{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[2114],{"nctId":2115,"briefTitle":2116,"status":761,"phases":2117,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2127},"NCT05808816","\"Lactobacillus Crispatus M247, LSIL and Microbiota\"",[91],"2023-02-02","2023-06-30","2021-06-16",90,[2123,2124,2125,2126],"Vaginal Flora Imbalance","ASC-US","LSIL","HPV Infection",[2102],{"trials":2129,"activeCount":100},[],{"intervention":2131,"totalTrials":122,"cells":2132},"Ranolazine",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2141,"NA":2154},{"trials":2134,"activeCount":100},[],{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[2143],{"nctId":2144,"briefTitle":2145,"status":2146,"phases":2147,"primaryCompletion":2148,"completion":2149,"start":2150,"enrollment":100,"conditions":2151,"interventions":2153},"NCT02687269","Ranolazine a Potential New Therapeutic Application","WITHDRAWN",[91],"2020-09","2020-10","2019-04-10",[2152],"Myocardial Stunning",[2131],{"trials":2155,"activeCount":100},[],{"intervention":2157,"totalTrials":122,"cells":2158},"Vitamin D",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2179},{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[],{"trials":2164,"activeCount":100},[],{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[2169],{"nctId":2170,"briefTitle":2171,"status":468,"phases":2172,"primaryCompletion":2173,"completion":2173,"start":2174,"enrollment":735,"conditions":2175,"interventions":2178},"NCT02020694","Vitamin D Supplementation for the Prevention of Cardiovascular Risk",[91],"2013-12","2011-12",[27,2176,2177],"Overweight","Insulin Resistance",[2157],{"trials":2180,"activeCount":100},[],{"intervention":2182,"totalTrials":122,"cells":2183},"Beclomethasone",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2192,"NA":2204},{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[2194],{"nctId":2195,"briefTitle":2196,"status":2146,"phases":2197,"primaryCompletion":2198,"completion":2199,"start":2200,"enrollment":100,"conditions":2201,"interventions":2203},"NCT02687100","The Effects of Beclomethasone Upper the Endotracheal Cuff on the Occurrence of Sore Throat at Extubation",[91],"2017-08","2017-09","2016-10",[2202],"Anesthesia, Endotracheal",[2182],{"trials":2205,"activeCount":100},[],{"intervention":2207,"totalTrials":122,"cells":2208},"Colistin",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2217,"NA":2229},{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219],{"nctId":2220,"briefTitle":2221,"status":761,"phases":2222,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":19,"conditions":2225,"interventions":2228},"NCT04995133","Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.",[91],"2022-01-30","2021-07-14",[2226,463,2227],"Hospital Infection","Critically Ill",[2207],{"trials":2230,"activeCount":100},[],{"intervention":781,"totalTrials":96,"cells":2232},{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2243,"PHASE4":2249,"NA":2251},{"trials":2234,"activeCount":100},[],{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[2239],{"nctId":772,"briefTitle":773,"status":761,"phases":2240,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":2241,"interventions":2242},[88,89],[779],[441,443,781,782],{"trials":2244,"activeCount":100},[2245],{"nctId":838,"briefTitle":839,"status":761,"phases":2246,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2247,"interventions":2248},[90],[15],[845,846,847,443,808,807,781],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"intervention":847,"totalTrials":96,"cells":2254},{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2261,"PHASE4":2271,"NA":2273},{"trials":2256,"activeCount":100},[],{"trials":2258,"activeCount":100},[],{"trials":2260,"activeCount":100},[],{"trials":2262,"activeCount":100},[2263,2267],{"nctId":838,"briefTitle":839,"status":761,"phases":2264,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2265,"interventions":2266},[90],[15],[845,846,847,443,808,807,781],{"nctId":796,"briefTitle":797,"status":468,"phases":2268,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":2269,"interventions":2270},[90],[803],[805,806,807,808,809,441],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"intervention":808,"totalTrials":96,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2293,"NA":2295},{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":100},[],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[2285,2289],{"nctId":838,"briefTitle":839,"status":761,"phases":2286,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2287,"interventions":2288},[90],[15],[845,846,847,443,808,807,781],{"nctId":796,"briefTitle":797,"status":468,"phases":2290,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":2291,"interventions":2292},[90],[803],[805,806,807,808,809,441],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"intervention":807,"totalTrials":96,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2315,"NA":2317},{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[],{"trials":2306,"activeCount":100},[2307,2311],{"nctId":838,"briefTitle":839,"status":761,"phases":2308,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2309,"interventions":2310},[90],[15],[845,846,847,443,808,807,781],{"nctId":796,"briefTitle":797,"status":468,"phases":2312,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":2313,"interventions":2314},[90],[803],[805,806,807,808,809,441],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[],{"intervention":805,"totalTrials":96,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2337,"PHASE4":2343,"NA":2345},{"trials":2322,"activeCount":100},[],{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[2327],{"nctId":2328,"briefTitle":2329,"status":468,"phases":2330,"primaryCompletion":2331,"completion":2331,"start":2332,"enrollment":788,"conditions":2333,"interventions":2336},"NCT02993705","Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)",[89],"2019-11-13","2017-02-22",[2334,2335],"Carcinosarcoma, Ovarian","Carcinosarcomas Uterine",[805],{"trials":2338,"activeCount":100},[2339],{"nctId":796,"briefTitle":797,"status":468,"phases":2340,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":2341,"interventions":2342},[90],[803],[805,806,807,808,809,441],{"trials":2344,"activeCount":100},[],{"trials":2346,"activeCount":100},[],{"intervention":2348,"totalTrials":122,"cells":2349},"Neuromuscular Blocking Agents",{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2354,"PHASE3":2356,"PHASE4":2367,"NA":2369},{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"trials":2355,"activeCount":100},[],{"trials":2357,"activeCount":100},[2358],{"nctId":2359,"briefTitle":2360,"status":2361,"phases":2362,"primaryCompletion":74,"completion":74,"start":2363,"enrollment":688,"conditions":2364,"interventions":2366},"NCT04012073","Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome","TERMINATED",[90],"2022-11-01",[2365],"Respiratory Distress Syndrome, Adult",[2348],{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"intervention":845,"totalTrials":122,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2385,"NA":2387},{"trials":2374,"activeCount":100},[],{"trials":2376,"activeCount":100},[],{"trials":2378,"activeCount":100},[],{"trials":2380,"activeCount":100},[2381],{"nctId":838,"briefTitle":839,"status":761,"phases":2382,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2383,"interventions":2384},[90],[15],[845,846,847,443,808,807,781],{"trials":2386,"activeCount":100},[],{"trials":2388,"activeCount":100},[],{"intervention":846,"totalTrials":122,"cells":2390},{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2403,"NA":2405},{"trials":2392,"activeCount":100},[],{"trials":2394,"activeCount":100},[],{"trials":2396,"activeCount":100},[],{"trials":2398,"activeCount":100},[2399],{"nctId":838,"briefTitle":839,"status":761,"phases":2400,"primaryCompletion":841,"completion":841,"start":763,"enrollment":842,"conditions":2401,"interventions":2402},[90],[15],[845,846,847,443,808,807,781],{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"intervention":2408,"totalTrials":122,"cells":2409},"COVID-19 Convalescent Plasma",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2428,"NA":2430},{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[2418],{"nctId":2419,"briefTitle":2420,"status":468,"phases":2421,"primaryCompletion":2422,"completion":2422,"start":2423,"enrollment":2424,"conditions":2425,"interventions":2427},"NCT04374526","Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.",[89,90],"2021-05-26","2020-05-27",29,[2426],"Coronavirus Disease 2019 )COVID-19)",[2408],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"intervention":2433,"totalTrials":122,"cells":2434},"Sugammadex 6 mg\u002Fkg",{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2455,"NA":2457},{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2444,"briefTitle":2445,"status":468,"phases":2446,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2451,"interventions":2453},"NCT04854993","Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy",[90],"2022-09-20","2022-09-23","2021-07-13",34,[1060,2452],"Neuromuscular Blockade",[2433,2454],"Sugammadex 4 mg\u002Fkg",{"trials":2456,"activeCount":100},[],{"trials":2458,"activeCount":100},[],{"intervention":2454,"totalTrials":122,"cells":2460},{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2473,"NA":2475},{"trials":2462,"activeCount":100},[],{"trials":2464,"activeCount":100},[],{"trials":2466,"activeCount":100},[],{"trials":2468,"activeCount":100},[2469],{"nctId":2444,"briefTitle":2445,"status":468,"phases":2470,"primaryCompletion":2447,"completion":2448,"start":2449,"enrollment":2450,"conditions":2471,"interventions":2472},[90],[1060,2452],[2433,2454],{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[],{"intervention":2478,"totalTrials":122,"cells":2479},"Subretinal injection of umbilical cord blood platelet-rich plasma",{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2486,"PHASE4":2499,"NA":2501},{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[],{"trials":2485,"activeCount":100},[],{"trials":2487,"activeCount":100},[2488],{"nctId":2489,"briefTitle":2490,"status":468,"phases":2491,"primaryCompletion":2492,"completion":2493,"start":2494,"enrollment":19,"conditions":2495,"interventions":2498},"NCT04636853","CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration",[90],"2021-12-01","2021-12-02","2020-12-23",[2496,2497],"Retinitis Pigmentosa","Dry Age-related Macular Degeneration",[2478],{"trials":2500,"activeCount":100},[],{"trials":2502,"activeCount":100},[],{"intervention":2504,"totalTrials":122,"cells":2505},"Antiviral Agents",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2510,"PHASE3":2512,"PHASE4":2521,"NA":2523},{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[],{"trials":2511,"activeCount":100},[],{"trials":2513,"activeCount":100},[2514],{"nctId":2515,"briefTitle":2516,"status":761,"phases":2517,"primaryCompletion":1367,"completion":1367,"start":2518,"enrollment":777,"conditions":2519,"interventions":2520},"NCT05735535","Women in Dual With Dolutegravir",[90],"2023-10-01",[33],[2504],{"trials":2522,"activeCount":100},[],{"trials":2524,"activeCount":100},[],{"intervention":2526,"totalTrials":122,"cells":2527},"Letrozole 2.5mg",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2532,"PHASE3":2534,"PHASE4":2548,"NA":2550},{"trials":2529,"activeCount":100},[],{"trials":2531,"activeCount":100},[],{"trials":2533,"activeCount":100},[],{"trials":2535,"activeCount":100},[2536],{"nctId":2537,"briefTitle":2538,"status":2361,"phases":2539,"primaryCompletion":2540,"completion":2541,"start":2542,"enrollment":2543,"conditions":2544,"interventions":2546},"NCT04421547","Efficacy of Letrozole in Recurrent Ovarian Cancer",[90],"2024-11-01","2024-11-04","2020-06-22",86,[2545],"Epithelial Ovarian Cancer",[2526,2547],"Standard single agent chemotherapy",{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"intervention":2547,"totalTrials":122,"cells":2553},{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2560,"PHASE4":2566,"NA":2568},{"trials":2555,"activeCount":100},[],{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"trials":2561,"activeCount":100},[2562],{"nctId":2537,"briefTitle":2538,"status":2361,"phases":2563,"primaryCompletion":2540,"completion":2541,"start":2542,"enrollment":2543,"conditions":2564,"interventions":2565},[90],[2545],[2526,2547],{"trials":2567,"activeCount":100},[],{"trials":2569,"activeCount":100},[],{"intervention":2571,"totalTrials":122,"cells":2572},"Pamrevlumab",{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2579,"PHASE4":2591,"NA":2593},{"trials":2574,"activeCount":100},[],{"trials":2576,"activeCount":100},[],{"trials":2578,"activeCount":100},[],{"trials":2580,"activeCount":100},[2581],{"nctId":2582,"briefTitle":2583,"status":468,"phases":2584,"primaryCompletion":1515,"completion":1515,"start":2585,"enrollment":714,"conditions":2586,"interventions":2590},"NCT05262309","An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19",[89,90],"2020-05-12",[2587,2588,2589],"COVID-19 Respiratory Infection","COVID-19 Pneumonia","Covid19",[2571],{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"intervention":809,"totalTrials":122,"cells":2596},{"EARLY_PHASE1":2597,"PHASE1":2599,"PHASE2":2601,"PHASE3":2603,"PHASE4":2609,"NA":2611},{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[],{"trials":2604,"activeCount":100},[2605],{"nctId":796,"briefTitle":797,"status":468,"phases":2606,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":2607,"interventions":2608},[90],[803],[805,806,807,808,809,441],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"intervention":770,"totalTrials":122,"cells":2614},{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2625,"PHASE4":2627,"NA":2629},{"trials":2616,"activeCount":100},[],{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[2621],{"nctId":759,"briefTitle":760,"status":761,"phases":2622,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":2623,"interventions":2624},[89],[768],[770,443,441],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[],{"trials":2630,"activeCount":100},[],{"intervention":2632,"totalTrials":122,"cells":2633},"Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine",{"EARLY_PHASE1":2634,"PHASE1":2636,"PHASE2":2638,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2635,"activeCount":100},[],{"trials":2637,"activeCount":100},[],{"trials":2639,"activeCount":100},[2640],{"nctId":2641,"briefTitle":2642,"status":761,"phases":2643,"primaryCompletion":2644,"completion":2645,"start":2646,"enrollment":2647,"conditions":2648,"interventions":2651},"NCT05371223","Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases",[89],"2025-05-30","2025-07-30","2022-03-01",38,[2649,2650],"Peritoneal Carcinomatosis","Pancreas Neoplasm",[2632],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"trials":2657,"activeCount":100},[],{"intervention":782,"totalTrials":122,"cells":2659},{"EARLY_PHASE1":2660,"PHASE1":2662,"PHASE2":2664,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2661,"activeCount":100},[],{"trials":2663,"activeCount":100},[],{"trials":2665,"activeCount":100},[2666],{"nctId":772,"briefTitle":773,"status":761,"phases":2667,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":2668,"interventions":2669},[88,89],[779],[441,443,781,782],{"trials":2671,"activeCount":100},[],{"trials":2673,"activeCount":100},[],{"trials":2675,"activeCount":100},[],{"intervention":2677,"totalTrials":122,"cells":2678},"PLD and Trabectedin rechallenge",{"EARLY_PHASE1":2679,"PHASE1":2681,"PHASE2":2683,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2680,"activeCount":100},[],{"trials":2682,"activeCount":100},[],{"trials":2684,"activeCount":100},[2685],{"nctId":2686,"briefTitle":2687,"status":761,"phases":2688,"primaryCompletion":2689,"completion":2689,"start":2690,"enrollment":584,"conditions":2691,"interventions":2693},"NCT04887961","Reprab Study: PLD + Trabectedin Rechallenge",[89],"2022-04-01","2020-10-01",[2692],"Relapsed Ovarian Cancer",[2677],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[],{"intervention":2701,"totalTrials":122,"cells":2702},"cord blood-RBC concentrates",{"EARLY_PHASE1":2703,"PHASE1":2705,"PHASE2":2707,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2704,"activeCount":100},[],{"trials":2706,"activeCount":100},[],{"trials":2708,"activeCount":100},[2709],{"nctId":2710,"briefTitle":2711,"status":468,"phases":2712,"primaryCompletion":2713,"completion":2713,"start":2492,"enrollment":2714,"conditions":2715,"interventions":2717},"NCT05100212","umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN)",[89],"2025-01-15",146,[2716],"Retinopathy of Prematurity",[2701,2718],"adult donor RBC concentrates",{"trials":2720,"activeCount":100},[],{"trials":2722,"activeCount":100},[],{"trials":2724,"activeCount":100},[],{"intervention":2718,"totalTrials":122,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2728,"activeCount":100},[],{"trials":2730,"activeCount":100},[],{"trials":2732,"activeCount":100},[2733],{"nctId":2710,"briefTitle":2711,"status":468,"phases":2734,"primaryCompletion":2713,"completion":2713,"start":2492,"enrollment":2714,"conditions":2735,"interventions":2736},[89],[2716],[2701,2718],{"trials":2738,"activeCount":100},[],{"trials":2740,"activeCount":100},[],{"trials":2742,"activeCount":100},[],{"intervention":2744,"totalTrials":122,"cells":2745},"Fentanyl Transdermal System",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2765,"PHASE4":2767,"NA":2769},{"trials":2747,"activeCount":100},[],{"trials":2749,"activeCount":100},[],{"trials":2751,"activeCount":100},[2752],{"nctId":2753,"briefTitle":2754,"status":468,"phases":2755,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":2758,"conditions":2759,"interventions":2763},"NCT04204967","Totally Transdermal Sedation in the Weaning From Remifentanil Infusion",[89],"2024-04-06","2021-02-15",24,[2760,2761,2762],"Respiratory Insufficiency","Ventilator Weaning","Analgesics, Opioid",[2744,2764],"Remifentanil",{"trials":2766,"activeCount":100},[],{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[],{"intervention":2764,"totalTrials":122,"cells":2772},{"EARLY_PHASE1":2773,"PHASE1":2775,"PHASE2":2777,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[],{"trials":2778,"activeCount":100},[2779],{"nctId":2753,"briefTitle":2754,"status":468,"phases":2780,"primaryCompletion":2756,"completion":2756,"start":2757,"enrollment":2758,"conditions":2781,"interventions":2782},[89],[2760,2761,2762],[2744,2764],{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"intervention":2790,"totalTrials":122,"cells":2791},"Up-front allogeneic hematopoietic stem cell transplantation",{"EARLY_PHASE1":2792,"PHASE1":2794,"PHASE2":2796,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2793,"activeCount":100},[],{"trials":2795,"activeCount":100},[],{"trials":2797,"activeCount":100},[2798],{"nctId":2799,"briefTitle":2800,"status":468,"phases":2801,"primaryCompletion":2802,"completion":1314,"start":2803,"enrollment":2804,"conditions":2805,"interventions":2807},"NCT03902665","Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75",[89],"2024-03-31","2019-03-15",19,[2806],"Acute Myeloid Leukemia, Adult",[2790],{"trials":2809,"activeCount":100},[],{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"intervention":792,"totalTrials":122,"cells":2815},{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2817,"activeCount":100},[],{"trials":2819,"activeCount":100},[],{"trials":2821,"activeCount":100},[2822],{"nctId":784,"briefTitle":785,"status":761,"phases":2823,"primaryCompletion":787,"completion":787,"start":459,"enrollment":788,"conditions":2824,"interventions":2825},[89],[790],[439,441,792],{"trials":2827,"activeCount":100},[],{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"intervention":2833,"totalTrials":122,"cells":2834},"Flurbiprofen",{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2839,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2836,"activeCount":100},[],{"trials":2838,"activeCount":100},[],{"trials":2840,"activeCount":100},[2841],{"nctId":2842,"briefTitle":2843,"status":761,"phases":2844,"primaryCompletion":2845,"completion":2846,"start":2847,"enrollment":975,"conditions":2848,"interventions":2850},"NCT04708964","Oro-tracheal Intubation: Flurbiprofen Subglottic Instillation to Prevent Laryngeal Inflammation",[89],"2021-06-30","2022-01-31","2021-01",[2849],"D010612",[2833,2851],"saline solution",{"trials":2853,"activeCount":100},[],{"trials":2855,"activeCount":100},[],{"trials":2857,"activeCount":100},[],{"intervention":2851,"totalTrials":122,"cells":2859},{"EARLY_PHASE1":2860,"PHASE1":2862,"PHASE2":2864,"PHASE3":2870,"PHASE4":2872,"NA":2874},{"trials":2861,"activeCount":100},[],{"trials":2863,"activeCount":100},[],{"trials":2865,"activeCount":100},[2866],{"nctId":2842,"briefTitle":2843,"status":761,"phases":2867,"primaryCompletion":2845,"completion":2846,"start":2847,"enrollment":975,"conditions":2868,"interventions":2869},[89],[2849],[2833,2851],{"trials":2871,"activeCount":100},[],{"trials":2873,"activeCount":100},[],{"trials":2875,"activeCount":100},[],{"intervention":2877,"totalTrials":122,"cells":2878},"Haplo SCT with NK cells",{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2897,"PHASE4":2899,"NA":2901},{"trials":2880,"activeCount":100},[],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[2885],{"nctId":2886,"briefTitle":2887,"status":2361,"phases":2888,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":2892,"interventions":2895},"NCT04166929","Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS",[89],"2023-09-28","2020-01-15",6,[2893,2894],"Acute Myeloid Leukemia","Myelodysplasia",[2877,2896],"Haplo SCT",{"trials":2898,"activeCount":100},[],{"trials":2900,"activeCount":100},[],{"trials":2902,"activeCount":100},[],{"intervention":2896,"totalTrials":122,"cells":2904},{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2915,"PHASE4":2917,"NA":2919},{"trials":2906,"activeCount":100},[],{"trials":2908,"activeCount":100},[],{"trials":2910,"activeCount":100},[2911],{"nctId":2886,"briefTitle":2887,"status":2361,"phases":2912,"primaryCompletion":2889,"completion":2889,"start":2890,"enrollment":2891,"conditions":2913,"interventions":2914},[89],[2893,2894],[2877,2896],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"trials":2920,"activeCount":100},[],{"intervention":2922,"totalTrials":122,"cells":2923},"N-Acetylcysteine",{"EARLY_PHASE1":2924,"PHASE1":2926,"PHASE2":2928,"PHASE3":2939,"PHASE4":2941,"NA":2943},{"trials":2925,"activeCount":100},[],{"trials":2927,"activeCount":100},[],{"trials":2929,"activeCount":100},[2930],{"nctId":2931,"briefTitle":2932,"status":761,"phases":2933,"primaryCompletion":2934,"completion":2935,"start":2936,"enrollment":11,"conditions":2937,"interventions":2938},"NCT05736887","Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19",[89],"2023-01-16","2023-06","2022-05-24",[29],[2922],{"trials":2940,"activeCount":100},[],{"trials":2942,"activeCount":100},[],{"trials":2944,"activeCount":100},[],{"intervention":2946,"totalTrials":122,"cells":2947},"Metformin",{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2949,"activeCount":100},[],{"trials":2951,"activeCount":100},[],{"trials":2953,"activeCount":100},[2954],{"nctId":2955,"briefTitle":2956,"status":2361,"phases":2957,"primaryCompletion":2958,"completion":2958,"start":2959,"enrollment":25,"conditions":2960,"interventions":2962},"NCT06884683","Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma",[89],"2023-09-13","2020-09-17",[2961],"Metastatic Renal Cell Carcinoma",[2946],{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"intervention":2970,"totalTrials":122,"cells":2971},"Vertistop® D",{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2973,"activeCount":100},[],{"trials":2975,"activeCount":100},[2976],{"nctId":2977,"briefTitle":2978,"status":468,"phases":2979,"primaryCompletion":2980,"completion":2980,"start":2981,"enrollment":2982,"conditions":2983,"interventions":2986},"NCT05748249","Evaluation of the Efficacy of Vertistop® D and Vertistop® L in the Prevention of BPPV Recurrence",[88],"2019-09-30","2018-11-01",126,[2984,2157,2985],"Benign Paroxysmal Positional Vertigo","Antioxidants",[2970],{"trials":2988,"activeCount":100},[],{"trials":2990,"activeCount":100},[],{"trials":2992,"activeCount":100},[],{"trials":2994,"activeCount":100},[],{"intervention":2996,"totalTrials":122,"cells":2997},"Fecal microbiota transplantation delivery through oral",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3012,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":2999,"activeCount":100},[],{"trials":3001,"activeCount":100},[3002],{"nctId":3003,"briefTitle":3004,"status":761,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":735,"conditions":3008,"interventions":3011},"NCT06368895","Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment",[88],"2025-06","2021-04-07",[3009,3010],"Hepatic Encephalopathy","Dysbiosis",[2996],{"trials":3013,"activeCount":100},[],{"trials":3015,"activeCount":100},[],{"trials":3017,"activeCount":100},[],{"trials":3019,"activeCount":100},[],{"intervention":3021,"totalTrials":122,"cells":3022},"study of molecular and protein pathways",{"EARLY_PHASE1":3023,"PHASE1":3034,"PHASE2":3036,"PHASE3":3038,"PHASE4":3040,"NA":3042},{"trials":3024,"activeCount":100},[3025],{"nctId":3026,"briefTitle":3027,"status":761,"phases":3028,"primaryCompletion":3029,"completion":470,"start":3030,"enrollment":735,"conditions":3031,"interventions":3033},"NCT05772754","Molecular Pathways Involved in Cardiac Remodeling in Patients With Chronic Heart Failure With Preserved Ejection Fraction by New Omics Technologies",[87],"2021-07-20","2020-12-18",[3032],"Coronary Heart Disease",[3021],{"trials":3035,"activeCount":100},[],{"trials":3037,"activeCount":100},[],{"trials":3039,"activeCount":100},[],{"trials":3041,"activeCount":100},[],{"trials":3043,"activeCount":100},[],{"intervention":3045,"totalTrials":96,"cells":3046},"Norepinephrine",{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3053,"PHASE4":3055,"NA":3067},{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[],{"trials":3054,"activeCount":100},[],{"trials":3056,"activeCount":100},[3057],{"nctId":3058,"briefTitle":3059,"status":761,"phases":3060,"primaryCompletion":3061,"completion":3061,"start":787,"enrollment":3062,"conditions":3063,"interventions":3066},"NCT05970770","Hypotension Prediction Index vs Norepinephrine Infusion for Prevention of Spinal Hypotension for Cesarean Delivery",[91],"2025-09-01",150,[3064,3065],"Hypotension During Surgery","Hypotension Drug-Induced",[3045],{"trials":3068,"activeCount":100},[3069],{"nctId":3070,"briefTitle":3071,"status":468,"phases":3072,"primaryCompletion":3073,"completion":3073,"start":3074,"enrollment":263,"conditions":3075,"interventions":3077},"NCT04560634","Diastolic Performance and Norepinephrine in Spinal-Induced Hypotension for Cesarean Delivery",[],"2020-12-15","2020-01-14",[3076],"Hypotension",[3045],{"intervention":3079,"totalTrials":96,"cells":3080},"Paracetamol",{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3087,"PHASE4":3089,"NA":3091},{"trials":3082,"activeCount":100},[],{"trials":3084,"activeCount":100},[],{"trials":3086,"activeCount":100},[],{"trials":3088,"activeCount":100},[],{"trials":3090,"activeCount":100},[],{"trials":3092,"activeCount":100},[3093,3103],{"nctId":3094,"briefTitle":3095,"status":468,"phases":3096,"primaryCompletion":3097,"completion":3097,"start":3098,"enrollment":3099,"conditions":3100,"interventions":3102},"NCT05025228","Analgesic Effect of Paracetamol in Patients With Femur Fracture: is Intravenous Better Than Oral?",[],"2020-06-30","2019-06-01",170,[3101],"Femur Fracture",[3079],{"nctId":3104,"briefTitle":3105,"status":468,"phases":3106,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":3110,"conditions":3111,"interventions":3113},"NCT05814302","Treatment Of Fever In The Emergency Department",[],"2022-06-01","2022-07-01","2021-06-01",324,[3112],"Fever",[3079],{"intervention":3115,"totalTrials":96,"cells":3116},"Ropivacaine",{"EARLY_PHASE1":3117,"PHASE1":3119,"PHASE2":3121,"PHASE3":3123,"PHASE4":3125,"NA":3127},{"trials":3118,"activeCount":100},[],{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"trials":3126,"activeCount":100},[],{"trials":3128,"activeCount":100},[3129,3141],{"nctId":3130,"briefTitle":3131,"status":468,"phases":3132,"primaryCompletion":3133,"completion":3134,"start":3135,"enrollment":460,"conditions":3136,"interventions":3139},"NCT04562103","Ropivacaine Plasma Concentration With or Without Epinephrine for Posterior Quadratus Lumborum Block",[92],"2020-08-03","2020-09-03","2020-07-03",[3137,3138],"Local Anesthetic Systemic Toxicity","Anesthesia, Local",[3140,3115],"Epinephrine \u002F Ropivacaine",{"nctId":3142,"briefTitle":3143,"status":468,"phases":3144,"primaryCompletion":3145,"completion":3146,"start":3147,"enrollment":3148,"conditions":3149,"interventions":3151},"NCT04814745","Intrathecal Morphine for Radical Robot Assisted Prostatectomy (TORNADO)",[92],"2021-01-30","2021-02-01","2020-07-07",33,[3150],"Catheter Related Complication",[3152,3153,3115],"intrathecal","Intravenous",{"intervention":3155,"totalTrials":122,"cells":3156},"Ferric carboxymaltose",{"EARLY_PHASE1":3157,"PHASE1":3159,"PHASE2":3161,"PHASE3":3163,"PHASE4":3165,"NA":3167},{"trials":3158,"activeCount":100},[],{"trials":3160,"activeCount":100},[],{"trials":3162,"activeCount":100},[],{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":100},[3169],{"nctId":3170,"briefTitle":3171,"status":468,"phases":3172,"primaryCompletion":1515,"completion":2846,"start":3173,"enrollment":3174,"conditions":3175,"interventions":3180},"NCT04744181","Patient Blood Management In CARdiac sUrgical patientS",[],"2021-01-18",479,[2094,3176,3177,3178,2096,3179],"Blood Loss Anemia","Iron-deficiency","Iron Deficiency Anemia","Erythropoiesis Abnormal",[3155,3181,3182],"B vitamin","Folic acid",{"intervention":3181,"totalTrials":122,"cells":3184},{"EARLY_PHASE1":3185,"PHASE1":3187,"PHASE2":3189,"PHASE3":3191,"PHASE4":3193,"NA":3195},{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"trials":3194,"activeCount":100},[],{"trials":3196,"activeCount":100},[3197],{"nctId":3170,"briefTitle":3171,"status":468,"phases":3198,"primaryCompletion":1515,"completion":2846,"start":3173,"enrollment":3174,"conditions":3199,"interventions":3200},[],[2094,3176,3177,3178,2096,3179],[3155,3181,3182],{"intervention":3182,"totalTrials":122,"cells":3202},{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3209,"PHASE4":3211,"NA":3213},{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[3215],{"nctId":3170,"briefTitle":3171,"status":468,"phases":3216,"primaryCompletion":1515,"completion":2846,"start":3173,"enrollment":3174,"conditions":3217,"interventions":3218},[],[2094,3176,3177,3178,2096,3179],[3155,3181,3182],{"intervention":3220,"totalTrials":122,"cells":3221},"direct anticoagulant",{"EARLY_PHASE1":3222,"PHASE1":3224,"PHASE2":3226,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3223,"activeCount":100},[],{"trials":3225,"activeCount":100},[],{"trials":3227,"activeCount":100},[],{"trials":3229,"activeCount":100},[],{"trials":3231,"activeCount":100},[],{"trials":3233,"activeCount":100},[3234],{"nctId":3235,"briefTitle":3236,"status":468,"phases":3237,"primaryCompletion":3238,"completion":2846,"start":3239,"enrollment":3240,"conditions":3241,"interventions":3243},"NCT04741334","Mild Head Injury, Antiplatelets, and Anticoagulants",[],"2021-12-31","2019-09-27",2127,[3242,1664],"Craniocerebral Trauma",[3220,3244,3245],"antiplatelet drugs","Dicumarols",{"intervention":3244,"totalTrials":122,"cells":3247},{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3258},{"trials":3249,"activeCount":100},[],{"trials":3251,"activeCount":100},[],{"trials":3253,"activeCount":100},[],{"trials":3255,"activeCount":100},[],{"trials":3257,"activeCount":100},[],{"trials":3259,"activeCount":100},[3260],{"nctId":3235,"briefTitle":3236,"status":468,"phases":3261,"primaryCompletion":3238,"completion":2846,"start":3239,"enrollment":3240,"conditions":3262,"interventions":3263},[],[3242,1664],[3220,3244,3245],{"intervention":3245,"totalTrials":122,"cells":3265},{"EARLY_PHASE1":3266,"PHASE1":3268,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3267,"activeCount":100},[],{"trials":3269,"activeCount":100},[],{"trials":3271,"activeCount":100},[],{"trials":3273,"activeCount":100},[],{"trials":3275,"activeCount":100},[],{"trials":3277,"activeCount":100},[3278],{"nctId":3235,"briefTitle":3236,"status":468,"phases":3279,"primaryCompletion":3238,"completion":2846,"start":3239,"enrollment":3240,"conditions":3280,"interventions":3281},[],[3242,1664],[3220,3244,3245],{"intervention":3283,"totalTrials":122,"cells":3284},"physiological solution",{"EARLY_PHASE1":3285,"PHASE1":3287,"PHASE2":3289,"PHASE3":3291,"PHASE4":3293,"NA":3295},{"trials":3286,"activeCount":100},[],{"trials":3288,"activeCount":100},[],{"trials":3290,"activeCount":100},[],{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[3297],{"nctId":3298,"briefTitle":3299,"status":468,"phases":3300,"primaryCompletion":3301,"completion":3301,"start":3302,"enrollment":3303,"conditions":3304,"interventions":3306},"NCT02958722","Comparison Between Two Different Distention Medium in Diagnostic Hysteroscopy",[92],"2017-04","2016-11",2000,[3305],"Hysteroscopy, Distension Medium, Pain",[3283,3307],"carbon dioxide",{"intervention":3307,"totalTrials":122,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3316,"PHASE4":3318,"NA":3320},{"trials":3311,"activeCount":100},[],{"trials":3313,"activeCount":100},[],{"trials":3315,"activeCount":100},[],{"trials":3317,"activeCount":100},[],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[3322],{"nctId":3298,"briefTitle":3299,"status":468,"phases":3323,"primaryCompletion":3301,"completion":3301,"start":3302,"enrollment":3303,"conditions":3324,"interventions":3325},[92],[3305],[3283,3307],{"intervention":3327,"totalTrials":122,"cells":3328},"Anti Covid 19 vaccination campaign for pregnat women",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3335,"PHASE4":3337,"NA":3339},{"trials":3330,"activeCount":100},[],{"trials":3332,"activeCount":100},[],{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[3341],{"nctId":3342,"briefTitle":3343,"status":468,"phases":3344,"primaryCompletion":3345,"completion":3345,"start":3346,"enrollment":882,"conditions":3347,"interventions":3351},"NCT05729191","Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer Among Pregnant Women",[],"2022-03-30","2021-10-25",[3348,3349,3350],"Pregnant Women","COVID 19 Vaccine","Vaccination Hesitancy",[3327],{"intervention":3353,"totalTrials":122,"cells":3354},"Alectinib 150 MG [Alecensa]",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3356,"activeCount":100},[],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[],{"trials":3362,"activeCount":100},[],{"trials":3364,"activeCount":100},[],{"trials":3366,"activeCount":100},[3367],{"nctId":3368,"briefTitle":3369,"status":468,"phases":3370,"primaryCompletion":3371,"completion":3371,"start":3372,"enrollment":3373,"conditions":3374,"interventions":3375},"NCT06339554","Alectinib-induced Endocrine Toxicity",[],"2023-10-30","2018-10-12",98,[426],[3353],{"intervention":3377,"totalTrials":122,"cells":3378},"Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).",{"EARLY_PHASE1":3379,"PHASE1":3381,"PHASE2":3383,"PHASE3":3385,"PHASE4":3387,"NA":3389},{"trials":3380,"activeCount":100},[],{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[],{"trials":3388,"activeCount":100},[],{"trials":3390,"activeCount":100},[3391],{"nctId":3392,"briefTitle":3393,"status":761,"phases":3394,"primaryCompletion":3395,"completion":3395,"start":2646,"enrollment":3396,"conditions":3397,"interventions":3399},"NCT05763472","Breast Cancer After Ovarian Cancer During and\u002For After Therapy: Genomic Evaluation",[],"2023-06-01",10,[3398],"BRCA-Associated Breast Carcinoma",[3377],{"intervention":3401,"totalTrials":122,"cells":3402},"Mepolizumab Auto-Injector",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3407,"PHASE3":3409,"PHASE4":3411,"NA":3413},{"trials":3404,"activeCount":100},[],{"trials":3406,"activeCount":100},[],{"trials":3408,"activeCount":100},[],{"trials":3410,"activeCount":100},[],{"trials":3412,"activeCount":100},[],{"trials":3414,"activeCount":100},[3415],{"nctId":3416,"briefTitle":3417,"status":761,"phases":3418,"primaryCompletion":3419,"completion":1230,"start":3420,"enrollment":3421,"conditions":3422,"interventions":3424},"NCT06258772","Mepolizumab in the Treatment of Patients With Severe Uncontrolled CRSwNP: a Multicentric Real Life Observational Study",[],"2025-02-01","2024-02-05",199,[3423],"Chronic Rhinosinusitis With Nasal Polyps",[3401],{"intervention":3426,"totalTrials":122,"cells":3427},"intraoperative near infrared (NIR) indocyanine green (ICG)-induced fluorescence angiography (FA) and air leak testing to assess the integrity and the perfusion levels of the colorectal anastomosis",{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3434,"PHASE4":3436,"NA":3438},{"trials":3429,"activeCount":100},[],{"trials":3431,"activeCount":100},[],{"trials":3433,"activeCount":100},[],{"trials":3435,"activeCount":100},[],{"trials":3437,"activeCount":100},[],{"trials":3439,"activeCount":100},[3440],{"nctId":3441,"briefTitle":3442,"status":761,"phases":3443,"primaryCompletion":39,"completion":3395,"start":3444,"enrollment":3445,"conditions":3446,"interventions":3448},"NCT04637061","Rectal Cancer Anastomosis 4 Check Study",[],"2021-01-01",287,[3447],"Rectal Cancer",[3426],{"intervention":3450,"totalTrials":122,"cells":3451},"Indocyanine green",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3462},{"trials":3453,"activeCount":100},[],{"trials":3455,"activeCount":100},[],{"trials":3457,"activeCount":100},[],{"trials":3459,"activeCount":100},[],{"trials":3461,"activeCount":100},[],{"trials":3463,"activeCount":100},[3464],{"nctId":3465,"briefTitle":3466,"status":761,"phases":3467,"primaryCompletion":868,"completion":2540,"start":3468,"enrollment":3469,"conditions":3470,"interventions":3472},"NCT05228587","Indocyanine Green Clearance Test in Liver Transplantation (LivInG)",[92],"2022-02-01",162,[3471],"Hepatic and Hepatobiliary Disorders",[3450],{"intervention":3474,"totalTrials":122,"cells":3475},"PIK3CA analysis",{"EARLY_PHASE1":3476,"PHASE1":3478,"PHASE2":3480,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3477,"activeCount":100},[],{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"trials":3483,"activeCount":100},[],{"trials":3485,"activeCount":100},[],{"trials":3487,"activeCount":100},[3488],{"nctId":3489,"briefTitle":3490,"status":761,"phases":3491,"primaryCompletion":787,"completion":787,"start":3492,"enrollment":3493,"conditions":3494,"interventions":3496},"NCT05750693","PIK3CA in HER2+ BC and pCR Trial",[92],"2022-05-02",58,[3495],"HER2-positive Breast Cancer",[3474],{"intervention":3140,"totalTrials":122,"cells":3498},{"EARLY_PHASE1":3499,"PHASE1":3501,"PHASE2":3503,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[],{"trials":3510,"activeCount":100},[3511],{"nctId":3130,"briefTitle":3131,"status":468,"phases":3512,"primaryCompletion":3133,"completion":3134,"start":3135,"enrollment":460,"conditions":3513,"interventions":3514},[92],[3137,3138],[3140,3115],{"intervention":3516,"totalTrials":122,"cells":3517},"Caplacizumab",{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3522,"PHASE3":3524,"PHASE4":3526,"NA":3528},{"trials":3519,"activeCount":100},[],{"trials":3521,"activeCount":100},[],{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[3530],{"nctId":3531,"briefTitle":3532,"status":761,"phases":3533,"primaryCompletion":3534,"completion":3534,"start":3535,"enrollment":122,"conditions":3536,"interventions":3538},"NCT05785468","A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)",[],"2023-03-30","2021-10-21",[3537],"Thrombotic Thrombocytopenic Purpura",[3516],{"intervention":3540,"totalTrials":122,"cells":3541},"Flu Vaccine",{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3543,"activeCount":100},[],{"trials":3545,"activeCount":100},[],{"trials":3547,"activeCount":100},[],{"trials":3549,"activeCount":100},[],{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[3554],{"nctId":3555,"briefTitle":3556,"status":468,"phases":3557,"primaryCompletion":3558,"completion":3559,"start":3560,"enrollment":3561,"conditions":3562,"interventions":3565},"NCT06304038","Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome",[],"2018-04-29","2019-11-14","2017-10-16",5483,[3563,3564],"Influenza Vaccine","Cost-Benefit Analysis",[3540],{"intervention":3567,"totalTrials":122,"cells":3568},"SGLT2 inhibitor",{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3573,"PHASE3":3575,"PHASE4":3577,"NA":3579},{"trials":3570,"activeCount":100},[],{"trials":3572,"activeCount":100},[],{"trials":3574,"activeCount":100},[],{"trials":3576,"activeCount":100},[],{"trials":3578,"activeCount":100},[],{"trials":3580,"activeCount":100},[3581],{"nctId":3582,"briefTitle":3583,"status":761,"phases":3584,"primaryCompletion":3585,"completion":3585,"start":3586,"enrollment":3587,"conditions":3588,"interventions":3591},"NCT05934071","Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril\u002FValsartan Therapy in Patients With HFrEF.",[],"2024-12-31","2022-10-10",160,[1260,3589,3590],"Ventricular Remodeling","Ventricular Dysfunction",[3567],{"intervention":3593,"totalTrials":122,"cells":3594},"Low volume macrogol",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3601,"PHASE4":3603,"NA":3605},{"trials":3596,"activeCount":100},[],{"trials":3598,"activeCount":100},[],{"trials":3600,"activeCount":100},[],{"trials":3602,"activeCount":100},[],{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[3607],{"nctId":3608,"briefTitle":3609,"status":468,"phases":3610,"primaryCompletion":3611,"completion":2845,"start":3612,"enrollment":3613,"conditions":3614,"interventions":3616},"NCT05362227","High-Volume Vs Low-Volume Preparation in Emergency Department",[92],"2021-05-30","2019-11-01",228,[3615],"GastroIntestinal Bleeding",[3593,3617],"High volume macrogol",{"intervention":3617,"totalTrials":122,"cells":3619},{"EARLY_PHASE1":3620,"PHASE1":3622,"PHASE2":3624,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3621,"activeCount":100},[],{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[],{"trials":3627,"activeCount":100},[],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[3632],{"nctId":3608,"briefTitle":3609,"status":468,"phases":3633,"primaryCompletion":3611,"completion":2845,"start":3612,"enrollment":3613,"conditions":3634,"interventions":3635},[92],[3615],[3593,3617],{"intervention":3637,"totalTrials":122,"cells":3638},"Lanreotide autogel",{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3640,"activeCount":100},[],{"trials":3642,"activeCount":100},[],{"trials":3644,"activeCount":100},[],{"trials":3646,"activeCount":100},[],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[3651],{"nctId":3652,"briefTitle":3653,"status":468,"phases":3654,"primaryCompletion":3655,"completion":3656,"start":3657,"enrollment":3658,"conditions":3659,"interventions":3661},"NCT06607666","Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands",[],"2024-01-31","2024-07-31","2023-01-26",102,[3660],"Acromegaly",[3637],{"intervention":3663,"totalTrials":122,"cells":3664},"COMIRNATY",{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3675},{"trials":3666,"activeCount":100},[],{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[3677],{"nctId":3678,"briefTitle":3679,"status":468,"phases":3680,"primaryCompletion":3238,"completion":3238,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3685},"NCT05781191","Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine",[],"2021-11-13",8231,[3684,29],"Influenza",[3663],{"intervention":3687,"totalTrials":122,"cells":3688},"Sufentanil NanoTab PCA System",{"EARLY_PHASE1":3689,"PHASE1":3691,"PHASE2":3693,"PHASE3":3695,"PHASE4":3697,"NA":3699},{"trials":3690,"activeCount":100},[],{"trials":3692,"activeCount":100},[],{"trials":3694,"activeCount":100},[],{"trials":3696,"activeCount":100},[],{"trials":3698,"activeCount":100},[],{"trials":3700,"activeCount":100},[3701],{"nctId":3702,"briefTitle":3703,"status":468,"phases":3704,"primaryCompletion":3705,"completion":3705,"start":3706,"enrollment":3707,"conditions":3708,"interventions":3713},"NCT03459404","Sufentanil NanoTab PCA System\u002F15 mcg for Acute Post-Operative Pain in Vertebral Surgery: A Preliminary Investigation",[],"2019-03-10","2018-09-19",17,[3709,3710,3711,3712],"Postoperative Pain","Spinal Fusion","Spondylolisthesis, Lumbar Region","Sufentanil",[3687],{"intervention":3715,"totalTrials":122,"cells":3716},"BRCA1\u002F2 genetic testing",{"EARLY_PHASE1":3717,"PHASE1":3719,"PHASE2":3721,"PHASE3":3723,"PHASE4":3725,"NA":3727},{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[],{"trials":3722,"activeCount":100},[],{"trials":3724,"activeCount":100},[],{"trials":3726,"activeCount":100},[],{"trials":3728,"activeCount":100},[3729],{"nctId":3730,"briefTitle":3731,"status":468,"phases":3732,"primaryCompletion":3733,"completion":3733,"start":3734,"enrollment":3735,"conditions":3736,"interventions":3738},"NCT05750719","BRCA and NACT in TNBC Patients",[],"2022-10-01","2013-01-02",136,[3737],"Triple-Negative Breast Cancer",[3715],{"intervention":3740,"totalTrials":122,"cells":3741},"exome sequencing",{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3746,"PHASE3":3748,"PHASE4":3750,"NA":3752},{"trials":3743,"activeCount":100},[],{"trials":3745,"activeCount":100},[],{"trials":3747,"activeCount":100},[],{"trials":3749,"activeCount":100},[],{"trials":3751,"activeCount":100},[],{"trials":3753,"activeCount":100},[3754],{"nctId":3755,"briefTitle":3756,"status":761,"phases":3757,"primaryCompletion":3758,"completion":3759,"start":3760,"enrollment":19,"conditions":3761,"interventions":3763},"NCT06080009","Analysis of Molecular Biomarkers in Periocular Adnexal Tumours",[92],"2024-10-06","2025-10-06","2023-10-31",[3762],"Sebaceous Cell Tumor of Eyelid",[3740],{"intervention":3765,"totalTrials":122,"cells":3766},"cytogenetic analysis on tumour tissue",{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3777},{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[],{"trials":3772,"activeCount":100},[],{"trials":3774,"activeCount":100},[],{"trials":3776,"activeCount":100},[],{"trials":3778,"activeCount":100},[3779],{"nctId":3780,"briefTitle":3781,"status":761,"phases":3782,"primaryCompletion":3783,"completion":3783,"start":3784,"enrollment":882,"conditions":3785,"interventions":3787},"NCT05889481","Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma",[],"2025-05","2008-01",[3786],"Uveal Melanoma",[3765,3788],"Digital Pathology",{"intervention":3788,"totalTrials":122,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3797,"PHASE4":3799,"NA":3801},{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":100},[],{"trials":3798,"activeCount":100},[],{"trials":3800,"activeCount":100},[],{"trials":3802,"activeCount":100},[3803],{"nctId":3780,"briefTitle":3781,"status":761,"phases":3804,"primaryCompletion":3783,"completion":3783,"start":3784,"enrollment":882,"conditions":3805,"interventions":3806},[],[3786],[3765,3788],{"intervention":3808,"totalTrials":122,"cells":3809},"HLA-genotyping",{"EARLY_PHASE1":3810,"PHASE1":3812,"PHASE2":3814,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3811,"activeCount":100},[],{"trials":3813,"activeCount":100},[],{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":100},[],{"trials":3821,"activeCount":100},[3822],{"nctId":3823,"briefTitle":3824,"status":468,"phases":3825,"primaryCompletion":3826,"completion":3826,"start":3827,"enrollment":3828,"conditions":3829,"interventions":3830},"NCT05711836","Role of HLA Genes and Innate Immunity in the Phenotypic Variability of COVID-19",[],"2022-09-01","2021-01-14",720,[29],[3808],{"intervention":3832,"totalTrials":122,"cells":3833},"disease modifying treatments",{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":100},[],{"trials":3839,"activeCount":100},[],{"trials":3841,"activeCount":100},[],{"trials":3843,"activeCount":100},[],{"trials":3845,"activeCount":100},[3846],{"nctId":3847,"briefTitle":3848,"status":761,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":44,"enrollment":3852,"conditions":3853,"interventions":3855},"NCT05769465","MAP THE SMA: a Machine-learning Based Algorithm to Predict THErapeutic Response in Spinal Muscular Atrophy",[],"2025-11-01","2026-04-01",247,[3854],"Spinal Muscular Atrophy",[3832],{"intervention":3857,"totalTrials":122,"cells":3858},"Genetic analysis of polymorphism of membrane receptors involved in lactate transport",{"EARLY_PHASE1":3859,"PHASE1":3861,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3860,"activeCount":100},[],{"trials":3862,"activeCount":100},[],{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[],{"trials":3868,"activeCount":100},[],{"trials":3870,"activeCount":100},[3871],{"nctId":3872,"briefTitle":3873,"status":761,"phases":3874,"primaryCompletion":3875,"completion":1566,"start":3876,"enrollment":3877,"conditions":3878,"interventions":3883},"NCT06222021","Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors",[92],"2025-08","2024-02",109,[3879,3880,3881,3882],"Surgical Procedure, Unspecified","Postoperative Complications","Hyperlactatemia","Abdomen Disease",[3857],{"intervention":3885,"totalTrials":122,"cells":3886},"BNT162b2 COVID-19 Vaccine",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3888,"activeCount":100},[],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"trials":3896,"activeCount":100},[],{"trials":3898,"activeCount":100},[3899],{"nctId":3900,"briefTitle":3901,"status":468,"phases":3902,"primaryCompletion":3903,"completion":3903,"start":3904,"enrollment":3905,"conditions":3906,"interventions":3907},"NCT05774418","Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.",[],"2021-03-31","2020-12-28",6649,[29],[3885],{"intervention":3909,"totalTrials":122,"cells":3910},"Rifaximin",{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3915,"PHASE3":3917,"PHASE4":3919,"NA":3921},{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"trials":3916,"activeCount":100},[],{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[3923],{"nctId":3924,"briefTitle":3925,"status":468,"phases":3926,"primaryCompletion":3927,"completion":3928,"start":3929,"enrollment":882,"conditions":3930,"interventions":3932},"NCT04077125","Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy",[],"2018-12-31","2019-03-01","2018-01-18",[3931],"Minimal Hepatic Encephalopathy",[3909],{"intervention":3934,"totalTrials":122,"cells":3935},"Atezolizumab in combination with nab-paclitaxel",{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3940,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3937,"activeCount":100},[],{"trials":3939,"activeCount":100},[],{"trials":3941,"activeCount":100},[],{"trials":3943,"activeCount":100},[],{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[3948],{"nctId":3949,"briefTitle":3950,"status":468,"phases":3951,"primaryCompletion":3952,"completion":3953,"start":3612,"enrollment":460,"conditions":3954,"interventions":3956},"NCT05609903","Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer",[],"2020-08-01","2022-05-31",[3955],"Breast Cancer Metastatic",[3934],{"intervention":3958,"totalTrials":122,"cells":3959},"Daratumumab",{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3961,"activeCount":100},[],{"trials":3963,"activeCount":100},[],{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":100},[],{"trials":3971,"activeCount":100},[3972],{"nctId":3973,"briefTitle":3974,"status":468,"phases":3975,"primaryCompletion":59,"completion":59,"start":1515,"enrollment":3976,"conditions":3977,"interventions":3981},"NCT05835726","Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.",[],188,[3978,3958,3979,3980],"Multiple Myeloma","Autologous Stem Cell Transplantation","Leukapheresis",[3958],{"intervention":3983,"totalTrials":122,"cells":3984},"neutrox",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3989,"PHASE3":3991,"PHASE4":3993,"NA":3995},{"trials":3986,"activeCount":100},[],{"trials":3988,"activeCount":100},[],{"trials":3990,"activeCount":100},[],{"trials":3992,"activeCount":100},[],{"trials":3994,"activeCount":100},[],{"trials":3996,"activeCount":100},[3997],{"nctId":3998,"briefTitle":3999,"status":761,"phases":4000,"primaryCompletion":4001,"completion":787,"start":3826,"enrollment":4002,"conditions":4003,"interventions":4008},"NCT05729321","Lock sOlutiOnS for Epicutaneo-caval Catheters in Neonates: a \"LOOSEN\" Pilot Study",[],"2022-11-05",7,[4004,4005,4006,4007],"Catheter-related Bloodstream Infection","Preterm","Catheter Infection","Catheter Complications",[3983],{"intervention":3152,"totalTrials":122,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":4012,"activeCount":100},[],{"trials":4014,"activeCount":100},[],{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[4023],{"nctId":3142,"briefTitle":3143,"status":468,"phases":4024,"primaryCompletion":3145,"completion":3146,"start":3147,"enrollment":3148,"conditions":4025,"interventions":4026},[92],[3150],[3152,3153,3115],{"intervention":3153,"totalTrials":122,"cells":4028},{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4030,"activeCount":100},[],{"trials":4032,"activeCount":100},[],{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[],{"trials":4038,"activeCount":100},[],{"trials":4040,"activeCount":100},[4041],{"nctId":3142,"briefTitle":3143,"status":468,"phases":4042,"primaryCompletion":3145,"completion":3146,"start":3147,"enrollment":3148,"conditions":4043,"interventions":4044},[92],[3150],[3152,3153,3115],{"intervention":4046,"totalTrials":122,"cells":4047},"Red Blood Cell concentrates from organ donor",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4049,"activeCount":100},[],{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[4060],{"nctId":4061,"briefTitle":4062,"status":468,"phases":4063,"primaryCompletion":74,"completion":74,"start":3395,"enrollment":3396,"conditions":4064,"interventions":4067},"NCT05835882","Blood Salvage From Liver Donors: a Feasibility Pilot Study",[92],[4065,4066],"Liver Transplantation","Erythrocyte Transfusion",[4046],{"intervention":4069,"totalTrials":122,"cells":4070},"Edoxaban",{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4075,"PHASE3":4077,"PHASE4":4079,"NA":4081},{"trials":4072,"activeCount":100},[],{"trials":4074,"activeCount":100},[],{"trials":4076,"activeCount":100},[],{"trials":4078,"activeCount":100},[],{"trials":4080,"activeCount":100},[],{"trials":4082,"activeCount":100},[4083],{"nctId":4084,"briefTitle":4085,"status":468,"phases":4086,"primaryCompletion":3029,"completion":4087,"start":4088,"enrollment":25,"conditions":4089,"interventions":4090},"NCT04271293","Oral Anti-coagulants in Fragile Patients With Percutaneous Endoscopic Gastrostomy and Atrial Fibrillation (ORIGAMI) Pilot Study",[],"2021-08-10","2020-04-07",[2069],[4069],{"intervention":4092,"totalTrials":122,"cells":4093},"Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"EARLY_PHASE1":4094,"PHASE1":4096,"PHASE2":4098,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"trials":4099,"activeCount":100},[],{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[],{"trials":4105,"activeCount":100},[4106],{"nctId":4107,"briefTitle":4108,"status":761,"phases":4109,"primaryCompletion":3733,"completion":2518,"start":4110,"enrollment":1002,"conditions":4111,"interventions":4112},"NCT05529784","Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)",[],"2021-10-06",[3423],[4092],{"intervention":4114,"totalTrials":122,"cells":4115},"Efficacy of a Standardized Intracameral Combination of Mydriatics and Anesthetic (Mydrane ®) for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma",{"EARLY_PHASE1":4116,"PHASE1":4118,"PHASE2":4120,"PHASE3":4122,"PHASE4":4124,"NA":4126},{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[],{"trials":4123,"activeCount":100},[],{"trials":4125,"activeCount":100},[],{"trials":4127,"activeCount":100},[4128],{"nctId":4129,"briefTitle":4130,"status":468,"phases":4131,"primaryCompletion":4132,"completion":4133,"start":4134,"enrollment":735,"conditions":4135,"interventions":4137},"NCT05925894","Efficacy Mydrane ® for Cataract Surgery in Patients With Concomitant Primary Open Angle Glaucoma.",[92],"2021-12-18","2022-01-09","2021-03-18",[4136],"Cataract Surgery",[4114],{"intervention":4139,"totalTrials":122,"cells":4140},"Herpes Zoster adjuvanted recombinant vaccine",{"EARLY_PHASE1":4141,"PHASE1":4143,"PHASE2":4145,"PHASE3":4147,"PHASE4":4149,"NA":4151},{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"trials":4146,"activeCount":100},[],{"trials":4148,"activeCount":100},[],{"trials":4150,"activeCount":100},[],{"trials":4152,"activeCount":100},[4153],{"nctId":4154,"briefTitle":4155,"status":468,"phases":4156,"primaryCompletion":4157,"completion":4158,"start":4159,"enrollment":4160,"conditions":4161,"interventions":4163},"NCT06334861","Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage",[],"2024-05-15","2024-07-30","2022-06-23",178,[4162],"Herpes Zoster",[4139],{"intervention":4165,"totalTrials":122,"cells":4166},"Chimeric Antigen Receptor",{"EARLY_PHASE1":4167,"PHASE1":4169,"PHASE2":4171,"PHASE3":4173,"PHASE4":4175,"NA":4177},{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":100},[],{"trials":4172,"activeCount":100},[],{"trials":4174,"activeCount":100},[],{"trials":4176,"activeCount":100},[],{"trials":4178,"activeCount":100},[4179],{"nctId":4180,"briefTitle":4181,"status":761,"phases":4182,"primaryCompletion":4183,"completion":4184,"start":4185,"enrollment":4186,"conditions":4187,"interventions":4189},"NCT06106776","CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study",[],"2024-11-02","2026-01-31","2023-11-02",48,[4188],"Lymphoma",[4165],{"intervention":4191,"totalTrials":122,"cells":4192},"Mepolizumab 300 mg",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4199,"PHASE4":4201,"NA":4203},{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"trials":4200,"activeCount":100},[],{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[4205],{"nctId":4206,"briefTitle":4207,"status":468,"phases":4208,"primaryCompletion":4209,"completion":4210,"start":4211,"enrollment":460,"conditions":4212,"interventions":4216},"NCT07592104","Effectiveness on Sino-Nasal Symptoms Of Mepolizumab 300",[],"2025-12-20","2026-03-23","2025-09-12",[4213,4214,4215],"Sinus Disease","EGPA - Eosinophilic Granulomatosis With Polyangiitis","Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps",[4191]]